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Abstracts 
Drug delivery particulates were prepared using alginate (ALG), poly-1-lysine 
(PLL) and pectin (PEC). Theophylline, chlorothiazide and indomethacin were used 
as the model drugs for in vitro dissolution, and mannitol was used as the model for 
assessing paracellular drug absorption across Caco-2 cell monolayers. ALG and 
PEC served as the core polymers; PLL helped to strengthen the particulate and PEC 
also helped to modulate the release profiles of the encapsulated model drugs. In 
vitro dissolution tests of ALG-PEC-PLL in acidic and alkaline media showed 
sustained drug release of the model drugs. In vitro bioadhesive tests indicated that 
the particulates had good bioadhesive properties. ALG and PEC also enhanced 
paracellular absorption of mannitol across Caco-2 mono layers by about three times. 
Use of ALG-PEC-PLL particulates is expected to combine the advantages of 
bioadhesion, absorption enhancement, and sustained release. This particulate 
system may have potential use as a carrier for poorly absorbed drugs by the oral 
route of administration . 
II 
In this study, the possibility of using melittin as a novel absorption enhancer 
was investigated. The membrane fusion peptide, melittin, is the major active 
ii 
ingredient of honey bee venom. Its action as a membrane fusion peptide on 
membrane has a strong concentration dependency. By incorporating melittin. which 
is itself a peptide, along with the drug in a particulate system, such as ALG-PEC-PLL 
particulates, we anticipate that a sufficient quantity of the drug and the enhancer will 
be delivered at the absorption site . Caco-2 cell line was used as the model cell line 
and mannitol was used as the model drug for transport study. MTT assay was 
performed to evaluate the cytotoxicity of melittin . The results indicated that at a 
concentration below 2.42 ~LM melittin did not show any cytotoxic effects on Caco-2 
cells. Transport study showed that 1 .20- 1.50 ~LM of melittin was able to increase 
the absorption of mannitol across Caco-2 cell monolayer by a factor of 3.5. 
Linking part I and II of the project 
The particulate system developed in part I, could be used to carry a drug and 
melittin (as an enhancer). It is envisaged that the pectin-alginate-poly lysine 
particulate will protect melittin (a peptide compound) in a biological environment that 
is 'hostile' to peptide molecules, thus enabling melittin to exercise its action as an 
absorption enhancer. This is an ongoing project and further work will be done in our 
laboratory. 
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Chapter I 
1. INTRODUCTION 
1.1 Development of bioadhesives in drug delivery systems 
1.1.1. Controlled-release drug delivery systems (COOS) 
Over the past 30 years, the therapeutic advantages of COOS have been 
recognized and greater attention has been paid to the development of COOS. The 
goals of COOS are to maintain effective blood concentrations of therapeutic agents 
throughout the dosage interval, to reduce the frequency of dosing or to increase 
effectiveness of the drug by localization at the site of action, to reduce the dose 
required and drug-induced side effects, or to provide uniform drug delivery. During 
the 1950's and early 1960's, the approach adopted to maintain effective plasma drug 
levels was through the use of dissolution/diffusion devices (Robinson, 1990). It is 
possible to only partially achieve these goals with the traditional COOS such as 
controlled-release tablets and capsules, etc., especially when orally administered, 
because the dosage form leaves the absorption site before it releases the drug 
completely. It is now generally accepted that drug absorption is largely dependent 
on the transit of the dosage form through the absorption sites, and variability in 
absorption is expected for most of the drugs (Park, 1986). Traditional COOS are not 
retained at the absorption site for a relatively long period oftime, hence, they can not 
offer significant therapeutic advantages over conventional, prompt release dosage 
forms. 
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Oral route of drug administration is the most accepted and popular 
administration route . Besides acceptance by the patients for its convenience of 
administration, it is more popular in the pharmaceutical industry because it can be 
mass produced easily with less cumbersome facilities. However, the development 
of oral COOS has been limited by the inability to restrain and localize the system in 
selected regions of the gastrointestinal (GI) tract. The transit time of most dosage 
forms in the Gl tract is about 8-12 h, and it is difficult to increase the absorption 
phase of administration beyond this time frame. Only absorption from the colon may 
allow continued drug delivery for up to 24 h. If a drug is absorbed by active 
transport. or at a specific region of the intestine, conventional sustained-release 
preparations may be unsuitable for absorption. One method to provide sustained 
delivery for such drugs is with low density pellets, capsules or tablets that can float 
in gastric juice, thus the gastric emptying can be delayed (Thanoo, et al., 1993 and 
Xu, 1991 ). However, this method is not su itable for drugs that are predominantly 
absorbed in the small intestine (Ichikawa, et al., 1991 ). In this context, the use of 
polymeric drug delivery systems that adhere to Gl mucus layer or epithelial cell 
surfaces holds promise and has attracted lots of attention. Such polymers are 
referred to as "bioadhesives". These bioadhesive polymeric COOS find potential 
application at many absorption sites with mucous membrane such as, nasal, buccal, 
intestinal and vaginal. In this research project we have developed a polymeric 
particulate system with bioadhesive property. The novelty of our DDS is in 
combining the advantages of particulates and bioadhesive technologies by using 
-2-
polymers of natural origin, alginate (ALG) and pectin (PEC). 
1.2. Bioadhesives 
A bioadhesive is defined as a synthetic or biological material which is capable 
of adhering to a biological substrate or tissue (Peppas, et al., 1985). The following 
characteristics art: believed to be essential for exhibiting the bioadhesive properties : 
i) molecular flexibility; ii) hydrophilic functional groups; and iii) a specific molecular 
weight (MW), chain length and conformation (Chien , 1992). The bioadhesive 
polymer binding with mucus at the mucosal membrane is referred to as a 
··mucoadhesive" polymer (Park, 1989). Since most of the bioadhesives interact with 
mucus before they can reach the mucosa, most bioadhesives presently available are 
actually mucoadhesives. In this thesis, the term bioadhesive is used to refer to all 
types of bioadhesives. 
A further classification of bioadhesives and bioadhesion is based on the 
presence or absence of non-biological (artificial) materials in the adhesion process 
(Park, et al. , 1990). The types of bioadhesion which have been identified are divided 
into three types. Type I refers to the adhesion of two biological substrates (e. g. cell 
aggregation), type II refers to the adhesion of a biological substrate to an artificial 
material (e. g. barnacle adhesion to a rock surface) and type Ill refers to the 
adhesion of artificial substances to biological substrates (e. g. the adhesion of 
polymers to mucosal epithelial). Type Ill bioadhesion has been investigated most 
by many research groups, including Robinson's group and Peppas's group and 
-3-
others (Robinson and Gauger, 1986; Robinson, 1990; Peppas, 1983; Peppas and 
Buri, 1985; Peppas and Robinson, 1995). 
1.2.1. Rationale for using bioadhesives 
Presently, extensive research has been done to investigate the mechanisms 
of bioadhesion , and to understand the phenomena at the molecular level (Kamath. 
et al., 1995). Mucus is the major factor in bioadhesion and has been studied 
thoroughly. Mucus usually refers to the layer covering the mucosa. The 
composition of mucus varies widely depending on animal species and anatomical 
locations. The mean thickness of the mucus layer varies from 50 to 450 ~tm in 
humans and about half of this thickness in the rat, depending on the site of location 
(Allen, et al. . 1985). It is secreted by the goblet cells in the epithelium or by special 
exocrine glands. Mucus is a translucent and viscid secretion. which forms a thin, 
continuous gel and adheres to the epithelial surface to protect the mucosa from 
external environment. The major components of mucus are high MW glycoproteins 
attached to oligosaccharide units. These units contain an average of about 8-10 
monosaccharide residues of five different types, and many of the terminal residues 
in the oligosaccharide side chains are sialic acid . Sialic acid has an axial carboxyl 
group which is an important source of negative charge for most mucus 
glycoproteins. Mucus is negatively charged at neutral pH and not charged at acidic 
pH. Numerous hydroxyl groups of carbohydrates on mucin molecules have the 
potential to interact with other polymers that can form hydrogen bonds (Johnson, et 
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al., 1972 and Kamath, et al . 1 995). Mucus also contains other fractions such as fatty 
acids and lipids, which aid in its protective function (Murty, et al., 1984). 
1.2.1.1. Mechanisms of bioadhesion 
The characteristics of mucus, such as negative charge and potential to form 
hydrogen bonds, are of great importance in promoting bioadhesion . Theories have 
been proposed to explain the bioadhesion phenomena which include electron 
transfer (Derjaguin, 1965), wetting (Baier, et al., 1968), diffusion (Peppas, et al., 
1983 and 1985), adsorption (Tabor, 1977), fracture and mechanical interlocking 
(Ponchel, et al., 1987 and Mikos, et al., 1988). Although these theories have 
provided some insights, no single theory can completely account for the bioadhesion 
phenomena and a combination of one or more factors are involved in the actual 
process. 
The adhesion between mucus and bioadhesives also has been analyzed 
based on molecular interactions, which provide further insights into bioadhesion . 
The interaction between two molecules is composed of attraction and repulsion . 
Attractive interactions arise from Van der Waal forces, hydrogen bonding, 
electrostatic attraction and hydrophobic interaction . Repulsive interactions occur 
because of electrostatic and steric repulsion. The magnitude of these two 
phenomena would determine how the molecules would bind. For bioadhesion to 
occur, the attractive interaction should be larger than nonspecific repulsion (Kamath. 
et al., 1995). 
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1.2.1.2. Advantages of bioadhesion 
Since most of the administration routes, such as oral, nasal, buccal, ocular, 
rectal, and vaginal, are coated with the mucus layer, bioadhesive drug delivery 
system (BODS) would be useful when applied at any of these mucosal membranes. 
B1oadhes1ves may be able to delay the transit of pharmaceutical dosage forms and 
increase the intimacy through their interaction with either the mucus or mucosa of 
the absorption sites (Veillard, 1990). Therefore, bioadhesion could overcome 
several problems of the traditional COOS. For instance, the extent of drug 
absorption from traditional COOS is limited by the residence time at the absorption 
site. As for orally administered dosage form, absorption is limited by the Gl transit 
time of the dosage form. In addition, many drugs are absorbed only from the upper 
part of the small intestine. Localizing oral drug delivery systems in the stomach or 
in the duodenum would significantly improve the extent of drug absorption . 
Bioadhesives may localize drugs in a particular region and prolong the residence 
time, thereby improve the bioavailability of those drugs with low bioavailability 
problems. 
In addition, strong interaction between bioadhesives and mucus on the tissue 
provides intimate contact between a dosage form and the epithelium which may 
result in high drug concentration in the local area. This intimate contact may 
increase the local permeability of poorly absorbed drugs by loosening tight junction 
or altering apical membrane of the epithelium (Harris, et al., 1990). Also, 
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bioadhesives may inhibit the enzymatic metabolism in a localized area. and protect 
the drug locally (Robinson. 1990 and Luessen et al., 1997). 
The above advantages put together seem very valuable for promoting the 
absorption of drugs that are poorly absorbed including macromolecules and peptides 
at mucosal sites. 
1.2.2. Factors influencing bioadhesion 
There are many factors that are important for the interaction between the 
bioadhesive and the mucus, which determine the strength and the extent of 
bioadhesion. These factors are described below. 
Initial contact time and initial pressure 
The initial contact time and the initial pressure between a bioadhesive and the 
mucus layer determine the extent of swelling and interpenetration of polymer chains. 
They can dramatically affect the performance of the bioadhesive. ln general, the 
bioadhesive strength increases as the initial contact time increases. If a high 
pressure is applied for a sufficiently long period of time, polymers become 
bioadhesive even though they may not have attractive interactions with mucus 
(Harris, et al., 1990). It is easy to control the initial contact time and pressure when 
bioadhesives are applied to exposed areas such as nose and mouth. However. for 
the application of bioadhesives to the Gl tract, the initial contact time cannot be 
controlled which is one of the difficulties in applying bioadhesives to the Gl tract. 
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pH 
pH is one of the important factors that affect bioadhesive strength, especially 
for polycationic bioadhesives, since mucus is negatively charged at neutral or alkine 
pH. Because of the strong interactions between oppositely charged electrolytes, 
polycations can be excellent bioadhesives at neutral pH. At low pH mucus is not 
charged and polycationic bioadhesives are far less effective. However. at low pH, 
polyanions are excellent bioadhesives due to their ability to form hydrogen bonds 
with numerous carbohydrate hydroxyl groups of mucin molecules. 
Extent of hydration 
The extent of hydration of the dosage form is related proportionally to the 
strength of bioadhesion. Hydration of the dosage form occurs by migration of water 
from the surrounding medium through the peripheral part of the dosage form. It is 
assumed that the greater the surface area of a dosage form, the greater the dosage 
form's bioadhesive strength. Therefore, it is better to have a lot of smaller 
microgranules or minitablets than a large size, thin tablet. On the other hand, over 
hydration will weaken the strength of the bioadhesion (Duchene, 1988). Thus, the 
extent of hydration should be monitored and controlled. 
Mucus turnover 
The natural turnover of mucus at the mucosal site is possibly the biggest 
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barrier to BODS. The mucus turnover limits the residence time of the bioadhesives 
on the mucus layer. No matter how high the bioadhesive strength, bioadhesives are 
sloughed off from the surface while mucus turnover happens. The turnover rate may 
be different in the presence of bioadhesives, but no information is available on this 
aspect. Mucus turnover leaves substantial amount of soluble mucin molecules on 
the epithelial membrane, which interact with bioadhesives before they have a 
chance to interact with the epithelial membrane. Mucus layer is very viscous and 
most bioadhesives can not penetrate this protective layer to interact with the 
epithelial membrane. This is why almost all the bioadhesives used now are actually 
mucoadhesives. From a few assumptions and experimental measurements of 
mucus output using total hexose of the perfusion solution , Allen et al ( 1985) 
calculated a mucin turnover time of47-270 min . The ciliated cells in the nasal cavity 
are known to transport the mucus to the throat at a rate of 5 mm/min (Gandhi , et al., 
1988). The mucociliary clearance in the tracheal region has been found to be in the 
range of 4 to 10 mm/min (Murty, et al., 1984). Peppas et al (1995) reported that 
residence time of the drug dosage forms for all mucosal routes was typically less 
than an hour unless some form of adhesive was employed as part of the drug 
delivery system. 
Gl motility and transit 
Oral administration is one of the most sought routes since it is the most 
convenient administration route but it also has the most complicated biological 
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environment. As for oral dosage forms, Gl motility and transit are very important 
which control the residence time and the absorption of the drug. They also affect the 
bioadhesion . Gl motility is under both nervous and hormonal control. Gastric 
emptying in the fasted state has a pattern termed the "migrating myoelectric 
complex" (MMC) which can be divided into four discrete phases of motility. The 
intensity of contractions (potential for gastric emptying) increases from almost zero 
in Phase I, to moderate in Phase II (mixing contractions), to very high in Phase Ill. 
The force of Phase Ill is strong enough to clear all indigestible materials from the 
stomach and the small intestine, but it lasts only for a short duration. Phase Ill is 
also called the housekeeper phase. Phase IV is the transitional period between 
Phases Ill and I. A complete cycle of these four phases has an average duration of 
90-120 min . This cycle of motility repeats itself until food is ingested, after that the 
stomach returns to its fed-state pattern of motility. Once in stomach the food goes 
through fed state, and the time for gastric emptying is about 2-6 h (Chien, 1992; 
Helliwell, 1993 ). 
The presence of the MMC has important implications for the oral delivery of 
BODS. BODS would need to be administered on an empty stomach to prevent 
adsorption to any ingested food. Ideally, one would hope to abtain attachment of the 
BODS to the mucosa of the stomach during Phase I of its cycle, at least initially, so 
that intimate contact could be achieved with the resultant formation of bioadhesive 
bonds. The high motility pattern of the stomach during Phase Ill of the MMC might 
not allow strong enough bioadhesion to occur if this was in operation during drug 
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administration. The optimal bioadhesive should be capable of adhering to the 
mucosal membrane strongly enough to withstand the shear force produced in the 
Phase Ill. However, the currently used bioadhesives can not meet such 
requirements. It has been suggested that it may be prudent to search for polymers 
that are able to induce a fed-like pattern of motility to the stomach in order to delay 
gastnc emptying and hence, increase dosage form transit time (Gruber, et al., 1988 ). 
The MMC also exists in the small intestine (but not in the large intestine), and 
each cycle lasts for up to half-an-hour longer than that experienced in the stomach 
(Chien, 1992). Motility within the small intestine takes the form of segmentation of 
mixing contractions and propulsive or peristaltic contractions. 
The transit of pharmaceutical dosage forms along the Gl tract has been 
extensively studied with the aid of gamma scintigraphy (Davis, et al., 1989; Roca. 
et al., 1991; Blok, et al., 1991 and Coupe, et al., 1992). The gastric emptying of 
doasge forms has been reviewed by Meyer (1989). It is evident that the presence 
of food in the stomach delays the emptying of dosage forms; the extent to which it 
is achieved depends on the food type. If the stomach is in Phase Ill of the MMC. 
then the dosage form may be ejected after only a few minutes. Most research on 
this topic has attempted to correlate the size of the dosage form with gastric 
emptying, but, no firm conclusions have been drawn yet. The maximum threshold 
size for gastric retention has been shown to range from 3 to over 1 0 mm, and hence 
it can only be stated that size has some poorly characterized effect on gastric 
emptying. 
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Small intestinal transit of dosage forms has been reviewed by Gupta and 
Robinson (1991 ). Briefly, in all instances the transit time of the small intestine is 3-4 
h. It also has been reported that during the MMC, solid dosage forms would reach 
the ileocaecal region from the pylorus in just under 2 h, compared with up to 6 h 
while in the fed state pattern of motility (Davis, 1989). Small intestinal transit is 
relatively constant and seems to be unaffected by pharmaceutical factors such as 
dosage form type, physiological factors such as age and exercise, and phathological 
conditions such as ulcerative colitis. In summary, the total transit time of foods and 
dosage forms in humans from stomach to the ileocecal junction is approximately 3-6 
h in the fasted state and 6-10 h in the fed state. This sets an approximately 10 h 
limit for the delivery of drugs absorbed solely from the small intestine region (Davis, 
1989 and Chien, 1992). 
Transit through the colon is highly variable and depends to some extent on 
the rate of gastric emptying. Colonic transit has been reviewed by Hardy (1989). 
The conclusions are listed as following. (i) Transit time for tablets and capsules is 
20-30 h, although much wider ranges have been reported. (ii) Transit time for 
solutions and microparticulates is about 30-40 h, which represents the greater 
spreading of such dosage forms in the ascending colon. (iii) Colonic transit is longer 
in females than in men, but it is generally unaffected by age in the range 20-70 
years. It was concluded that the range of transit times experienced in the colon 
must be taken into account during the administration ofthe formulations intended for 
drug delivery to the colon. 
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1.3. Current research in drug delivery using BODS 
1.3.1. General information 
The first generation of bioadhesives has been available for some time. At the 
very beginning, bioadhesion dealt mostly with the buccal administration of solid 
dosage forms and especially tablets (Nagai, et ai., 1990). This was due to the easy 
accessibility of the mucosa, and the simple process of tablet manufacture. This 
concept rapidly led to the idea that bioadhesion could be used advantageously to 
improve drug absorption through other administration routes, such as the nasal, 
ocular, vaginal and colonic routes (Duchene, et ai., 1988; Saettone, et al., 1989 and 
Hou, et al., 1985). A significant progress has occurred in this field and a better 
understanding of the mechanism of interaction between the bioadhesive and the 
mucosa has resulted in the targeting of polymers to specific receptors (Peppas. 
1995). 
Each administration route has its advantages and drawbacks. For instance. 
administration of drugs by buccal route helps in avoiding destruction of drugs by the 
Gl fluids and bypassing hepatic first pass metabolism, but it is difficult to retain the 
dosage form in the mouth for prolonged period without swallowing it. Rectal 
administration of drugs, for systemic treatment, may have improved absorption and 
higher plasma concentration due to avoidance of hepatic first pass but retaining at 
the absorption site for a prolonged period is a major concern. For all these routes 
such as buccal, nasal, rectal, vaginal and oral, it is desirable that the dosage form 
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is not eliminated prematurely from the absorption site. Bioadhesives may provide 
the possibility of retaining the dosage forms at the absorption sites and prolonging 
the residence time. 
In recent years, nasal administration of drugs has achieved great success as 
an alternative to oral route. Commercially available products that are given via the 
nasal route include LHRH, vasopressin and analogues, and calcitonin. However, 
mucus turnover in the nasal cavity is still a major limitation for sustained nasal drug 
delivery. Some bioadhesives such as microcrystalline cellulose, neutralized 
carboxymethylcellulose and chitosan, have been employed to improve the residence 
time of the drug on the absorption site. Use of bioadhesives in nasal drug delivery 
in prolonging the residence time showed great potential. Few polymeric 
bioadhesives such as chitosan also exhibited permeability enhancement (Nagai, et 
al., 1984 and Ilium et al., 1994a). In vaginal administration, a non-hormanal drug-
free bioadhesive vaginal moisturizer, Replens~. has been used to treat the vaginal 
dryness. Replens® has significantly improved therapeutic effect and patient 
compliance compared to estrogen vaginal cream (Nachtigal!, 1994 ). 
As eluded above, Gl transit and degradation limit the usefulness of orally 
administered drugs. Such limitations have led to several approaches such as the 
incorporation of drugs into bioadhesive polymers for the preparation of oral BODS. 
For water soluble drugs it is possible to use bioadhesive polymers to coat the 
surface of the dosage form, either totally or partially, which results in the prolonged 
retention on the mucosa, and the release rate of the drug is controlled by the 
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dissolution rate across the polymer used . For sparingly water soluble drugs, a 
gelling polymer can be used to trap the drug which would result in a slow release of 
drug because of reduced diffusion. Drugs also can be directly dispersed into a 
bioadhesive polymer to form a matrix type drug delivery system, or the matrix 
formulation can be further coated by a bioadhesive with a similar or different 
structure (Chien , 1992). Experiments in rats showed that bioadhesive polymers 
prolonged stomach emptying and increased the residence time of the drug in 
stomach. Some bioadhesives, such as polyacrylic polymers, are also speculated to 
inhibit the proteolytic activity of trypsin and carboxypeptidase A. Therefore. they are 
expected to improve oral absorption of drugs including peptides and proteins (Ch 'ng. 
et al.. 1 985; Luessen. et al.. 1 993 and 1 994 ). 
1.3.2. Some commonly used bioadhesives 
Earlier work examined binding of a broad spectrum of polymers to mucin-
epithelial cell surfaces. The studies indicate that in general , anionic polymers are 
preferred over neutral or cationic polymers because they are relatively non-toxic and 
are suitable to form strong adhesion through hydrogen bonds. Water-insoluble 
polymers provide greater flexibility in dosage form design as compared with rapidly 
or slowly dissolving water-soluble polymers ( Park, et al.. 1984 ). Polycations are 
believed to interact with membrane-associated anionic sites to induce morphological 
alterations that could result in the loss of membrane integrity and cellular rigidity 
(Quinton, 1973). 
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It has been suggested that polyanions with a high charge density are highly 
active bioadhesives (August, et al., 1 988a). Various polyanions have been 
evaluated, and the polymers containing carboxylic functional groups, such as 
polyacrylic polymers, show very high levels of bioadhesion (Scheuplein, 1966). 
Table 1 lists some commonly used pharmaceutical excipients in relation to their 
bioadhes1ve properties (Chien, 1 992). 
Hydrophilic polymers, such as carboxymethylcellulose (CMC) and 
hydroxypropylcellulose (HPC), are commonly used in pharmaceutical industry. 
Besides other polymeric properties, they have very good bioadhesive property. In 
the table presented above, they are on top rank of bioadhesive strength . They also 
have been used in combinations, such as a mixture of Carbopol® and HPC (Nagai, 
1985), combinations of CMC, pectin and gelatin (Ranga Rao and Buri. 1989), etc .. 
Presently polyacrylic polymers (e.g. polycarbophil and Carbopol®) have been widely 
studied as model bioadhesives. In v;tro and in vivo tests showed that polycarbophil 
and Carbopol® had very high bioadhesive strengths (Smart, et al., 1984 and Anlar, 
et al., 1993) and could inhibit the intestinal proteolytic enzyme trypsin (Luessen, et 
al., 1997). Harris et al (1989) investigated the feasibility of using bioadhesive 
polymers to extend the Gl transit time in rats and humans. The results obtained in 
rats indicated that among the investigated polymers, polyacrylic polymers, such as 
polycarbophil and Carbopol®, had potential in delaying Gl transit. However, the 
major delay was due to a decrease in the gastric emptying time. Hydrogels, such 
as Carbopol® 934p, may be useful for formulation of a sustained-release nasal 
-16-
delivery system since they can achieve a long-term intimate contact with the nasal 
mucosa and thus provide a prolonged therapeutic effect without suppressing 
mucociliary functions (Zhou, 1996). 
Gums, alginate, carrageenan, gum arabic and pectin usually form a 
mucilaginous solution in water and become sticky. They are another group of 
bioadhesives with good bioadhes1ve properties. Alginates have been stud1ed 
extensively because they can form hydrogel. 
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Table 1. Relative mucoadhesive performance of some potential and 
commonly used bioadhesive pharmaceutical polymers 
Relative Qualitative 
Polymers mucoadhesive bioad hesive 
force a propertyb 
Carboxymethylcellu lose 193 Excellent 
Carbopol® 185 Excellent 
Polycarbophil Excellent 
Tragacanth 154 Excellent 
Na Alginate 126 Excellent 
HPMC 125 Excellent 
Gelatin 116 Fair 
Pectin 100 Poor 
Acacia 98 Poor 
Providone 98 Poor 
a Percentage of a standard, tested in vitro (Smart, et al., 1984) 
b Assessed in vivo (Satoh, et al.. 1989) 
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1.3.3. Some novel bioadhesive polymers 
Although hydrogels and hydrophilic polymers have been traditionally thought 
of as good bioadhesive systems, new results suggest that novel materials with 
greater bioadhesive properties may exist (Lehr, et al., 1993). The results obtained 
by Chickering (1995) group using a novel electrobalance-based method showed that 
one group of bioerodible polyanhydrides (co-polymers of fumaric acid and sebacic 
acid) produced strong bioadhesive interactions in in vitro experiment, compared to 
other thermoplastic and hydrogel materials. These findings strongly supported the 
existence of bioadhesion between soft tissue and hard, bioerodible, thermoplastic 
polymers. Correlation between the in vitro findings and their in vivo performance is 
still under investigation. 
1.3.4. Development of bioadhesive formulations in the market 
At present, several drugs in the market have bioadhesive formulations . They 
are listed in Table 2. 
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Table 2. Some bioadhesive formulations in the market (Kamath, 1 995) 
Name and Form Drug Mucoadhesive Application Site 
Attach tablet Triamcinolone Hyd roxypropyl Oral Cavity 
Acetonide cellulose, Carbopol 
934 
Susadrin tablet Nitroglycerin Synchron (modified Buccal 
HPMC) 
Buccastem tablet Prochlorperazine Ceratonia, Xanthan Buccal 
maleate gum 
Salcoat powder Beclomethasone Hydroxypropyl Oral cavity 
spray dipropionate cellulose 
Solcoseryl paste Gingival 
Orabase gel NaCMC, pectin, and Oral cavity 
gelatin in 
polyethylene-mineral 
oil base 
Orahesive NaCMC, pectin, and Oral cavity 
bandage gelatin in poly-
isobutylene spread 
onto polyethylene 
film 
Rhinocort Beclomethasone Hydroxypropyl Nasal 
powder spray dipropionate cellulose 
Replens gel Polyacrylic acid Vaginal 
Sucralfate Aluminum Sucorse octasu \fate Gl tract ulcers 
hydroxide 
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1.3.5. Oral drug delivery using novel bioadhesives 
Most of the currently used bioadhesive polymers can not achieve the 
desirable prolonged residence time by oral route. Hence, research groups are 
exploring new bioadhesive candidates, which have site-specific adhesion property, 
to meet this challenge. In the last few years. lectins have attracted the interest of 
pharmaceutical scientists because of their ability to accomplish specific binding to 
membrane bound sugar moieties located at the surface of epithelial cells. Another 
advantage of lectins is their generally good resistance to digestion within the Gl tract 
(Haltner. et al., 1997). Severallectins have already been investigated in the light of 
possible pharmaceutical applications (Florence, et al., 1995, Lazarova, et al., 1993 
and lrache, et al., 1994 ). Tomato lectin, a non-toxic dietary glycoprotein of molecular 
mass 71 kDa, has been studied thoroughly by Naisbett et al (1994a, 1994b and 
1995) in both in vitro and in vivo experiments. The in vitro results showed very 
exciting promise that tomato lectin bind with the enterocyte cell surface due to the 
specific lectin-sugar interaction. However, the in vivo results did not correlate with 
the in vitro results, and this might be due to interactions of tomato lectin with 
intestinal mucus limiting its use as an intestinal bioadhesive. Other in vivo 
experiments are under progress. 
The concepts of specific en do- and transcytosis of bioadhesive ligands have 
been introduced into this field. These include receptor-mediated endo- and 
transcytosis, adsorptive endo- and transcytosis mediated by electrostatic (charge-
mediated) and sugar-specific (lectin-mediated) interaction. As a major difference to 
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the previous attempts to nonspecifically increase the permeability of an epithelial 
barrier in general, such specific, receptor-mediated absorption enhancement are 
expected to affect only the substrate concerned, whereas the barrier function of the 
epithelium against all other solutes remains intact. The uptake of Vitamin B 12 is 
receptor-mediated transcytosis through epithelial cells. Russel-Jones and de 
Aizpurua ( 1988) prepared conjugates of Vitamin B 12 and an analogue of luteinizing 
hormone-releasing hormone (LHRH). The oral administration of this conjugate to 
mice stimulated ovulation in developing follicles whereas the free hormone did not. 
This result suggested that the Vitamin 812 pathway provided a means to deliver 
macromolecules at physiologically relevant quantities. However, whether the total 
capacity of this transport mechanism will be sufficient for systemic drug delivery or 
merely for the delivery of trace amounts of macromolecular antigens still remains to 
be proved (lehr, 1994 ). 
1.3.6. Colonic drug delivery by oral route 
The delivery of drugs to the colon for systemic action or a local effect is 
valuable in a variety of circumstances. Many studies indicate that due to the lower 
proteolytic activity in the colon compared to the small intestine, colon-specific drug 
carriers may potentially be used for the delivery of peptide and protein drugs 
(Rubinstein, et al., 1997). 
Several bioadhesives, such as polycarbophil, Carbopol® 934 and pectin, have 
been investigated for drug delivery to the colon. Besides having bioadhesive 
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properties, the loosely crosslinked acrylic polymers Carbo pol® 934 and polycarbophil 
have been shown to inhibit enzymatic degradation (luessen . et al., 1993 and 1994 ). 
However, a major drawback of polycarbophil and Carbopol® 934 is their extremely 
high swelling properties, which cause them to disperse in aqueous solutions within 
several minutes (luessen. et al., 1994 ). A possible outcome of these studies is that 
a core tablet made of polycarbophil or Carbopol'm 934, coated with a colon-specific 
biodegradable polymer. could be an efficient delivery system for peptide and protein 
drugs to the colon . 
The natural polysaccharide pectin or its low water soluble product, calcium 
pectinate, is non-toxic, almost totally degraded by colonic bacteria and is not 
digested by gastric or intestinal enzymes (Ashford, et al., 1993a, 1994 and 
Rubinstein, et al., 1995). It has been demonstrated that compression coats of pectin 
in human (Ashford, et al. , 1993b) and calcium pectinate in dogs (Rubinstein , et al., 
1995) were able to retard the release of model drugs long enough for the drugs to 
arrive to the large intestine. In this research project we have explored the possibility 
of using alginate and pectin together to benefit from both their properties. 
1.4. Bioadhesive particulate system 
Much advancement in drug delivery could come from improvement of the 
existing systems. The concept of combining the advantages of particulates and 
bioadhesive technologies in one delivery system is attractive because of its potential 
capability of delivering peptide and protein drugs (Ponchel, ~~tal., 1997). While the 
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bioadhesive part of the formulation could enhance the peptide delivery by prolonging 
its retention, localizing the drug at the site of absorption and intensifying the 
concentration gradient (Lehr, et al. , 1994 ), the particulate part of the formulation 
could act as a carrier for the drug and protect it from the harsh physiological 
environment. 
Attempts to use bioadhesive particulates to deliver drugs including peptides 
and proteins have been made by some groups such as Ilium group and Mathiowitz 
group (Chickering et al., 1997), and the results showed some promise for the drug 
delivery. For instance, for the development of bioadhesive particulate systems, 
albumin, starch and diethylaminoethyl (DEAE)-dextran were used as the formulation 
base and administered by nasal route. This study demonstrated that it is possible 
to control the release of drugs from the bioadhesive particulate system. The results 
showed that the particulate prepared from starch and DEAE-Sephadex® were 
effective in delaying nasal muco ciliary clearance (Ilium, et al., 1987). Ilium group 
( 1994) also reported that hyaluronic acid ester microspheres significantly enhanced 
the intranasal absorption of insulin in sheep, and bioadhesive starch microspheres, 
especially in combination with an absorption enhancer, lysolecithin, had a profound 
effect on the absorption of desrnopressin in sheep, with bioavailabilities reaching 
nearly 10% compared with 1 .2% for a simple nasal solution of desmopressin. 
Likewise, a microcapsule system (100- 500 ~-tm) with a bioadhesive coating 
that consists of polyhydroxy methcrylate (p-HEMA) and a bioadhesive coating, 
Carbopol® 943/Eudragit® RL-100 (9:1) blend has been developed . This system was 
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examined and found to substantially increase the mean residence time in the Gl tract 
by two-fold when compared to uncoated microcapsules. The adhesive interaction 
was also studied and the results showed that the bioadhesive coated microcapsules 
clearly adhered to the mucosal tissue. whereas the non-coated microcapsules 
circulated freely in the solution (Chien, 1992). 
Investigation of bioadhesive polymer polycarbophil-coated albumin beads 
indicated that the gastric retention time was substantially prolonged by the 
bioadhesive coating. Therefore, the systemic bioavailability ofthe incorporated drug 
was significantly improved with an increase in the drug plasma concentration 
(longer. et al., 1985). 
Besides, some other bioadhesive particulate systems have been developed 
such as poly (fumaric-co-sabacic anhydride) microspheres, etc. However, these 
methods either use organic solvent during preparation or have complicated 
preparation procedures, which are incompatible with many labile drugs including the 
peptide and protein drugs. The methods involving organic solvent also have the 
possibility of residual toxicity due to trace amount of organic solvent left in the 
preparation. 
Anionic polysaccharide ALG and cationic polysaccharide chitosan, used for 
various purposes in pharmaceutical drug formulations due to their good 
biocompatibility, biodegradability and low toxicological properties, have good 
bioadhesive properties (Table 1 and Smart, et al., 1984 ). There is a relatively simple 
procedure for the preparation of both ALG and chitosan particulates since they can 
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form the hydrogel by ionotropic interactions. The procedure is performed in a mild 
aqueous environment which would be more suitable for carrying labile drugs 
including peptide and protein drugs (Bodmeier, et al., 1989, 1990 and 1994 ). 
However, ALG particulates are fragile in the presence of monovalent cations (e.g., 
sodium ions), and chitosan particulates are fragile in the presence of monovalent 
anions (e .g., chloride ions) . 
Alg inate-poly-/-lysine-alginate (ALG-PLL-ALG) microcapsules containing 
bioactive cells have been reported and patented to be used for transplantation (Lim, 
et al., 1980 and Uludag, et al., 1993). Calcium ions cross-link the ALG species, 
initially in solution as the sodium salt, and form the calcium-ALG hydrogel. The 
addition of an oppositely charged polyelectrolyte (e .g. PLL) allows a layer of 
insoluble polyelectrolyte complex to form at the interface of the hydrogel . Finally, the 
calcium ions remaining in the interior of the microcapsule are exchanged with an 
excess of sodium ions in diluted sodium ALG solution, rendering the interior fluid 
again. The microcapsules are formed under mild conditions (e. g., no extremes of 
pH, no chemical reactions). Their ability to entrap the cells also makes them an 
attractive candidate for controlled-release dosage forms . 
Pectin has been used to coat the tablets due to its characteristics of forming 
insoluble pectate in the presence of calcium ions, and this formulation has been 
used to deliver the drug to the colon. The experimental results showed that drug 
could reach the colon after administered this dosage formulation (Ashford, et al., 
1993). 
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As eluded earlier all of these particulates individually have limited utility due 
to either lack of robustness or inability to control drug release. Hence, we have 
attempted to combine the properties of alginate, PLL and pectin in preparing a novel 
particulates that is robust, able to sustain drug release and has bioadhesive 
property. 
1.5. Test methods used to study bioadhesion 
The main purpose of bioadhesives is to secure the dosage form to a certain 
site in the body, thereby increase the drug absorption. Bioavailability can be used 
as an ultimate parameter to test the performance of bioadhesives. However, in vivo 
bioavailability test is very expensive and time-consuming, and therefore cannot be 
used as a routine method to prescreen the bioadhesive properties of various 
polymers. For this reason, many investigators proposed and used simple test 
methods, such as measurement of residence time, measurement of in vitro adhesive 
strength, etc., to study the bioadhesive properties. These tests are very useful and 
necessary because they can not only screen a large number of bioadhesive 
candidates, but also help in elucidating the mechanisms of bioadhesion without 
affecting the complicated physiological factors. Some of the commonly used 
methods for BODS study are briefly described below. 
1.5.1. In vitro test methods 
In vitro tests are preformed in controlled environments and some of them 
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might bear no relationship to the ultimate performance of the BODS. Nevertheless, 
in vitro tests provide useful and preliminary information of the dosage form and can 
be correlated to in vivo situation to some extent. 
1.5.1.1. Adhesive strength tests 
Adhesive strength tests include tensile, shear and peel strength. Of these. 
and tensile strength test is the most commonly employed in vitro test. It measures 
the weight per area or the force required to detach a bioadhesive substance from a 
biological substrate, such as a mucosal epithelium (Smart, et al., 1982 and 1984; 
Peppas, et al., 1985; Park, et al., 1985; Ponchel, et at., 1987; Leung, et al., 1988; 
Robert, 1988; Lehr, eta!., 1990; Bottenberg, etal. , 1991 and Smart, 1991). Briefly, 
the bioadhesive under examination is attached to the under-surface of a solid 
support, which is connected to a torsion balance via a pulley. The test bioadhesive 
is lowered onto the biological substrate and left for a predetermined period to allow 
interaction between the material and the biological tissue. After this period, the solid 
support is raised at a constant rate until total detachment occurs and the maximum 
weight required indicates the adhesive strength of the test sample. Numerous 
modifications of the standard have been reported to be used for this test. Since, 
there is no criterion for this test, different equipments give different values of the 
adhesive strength. 
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1.5.1.2. Perfusion tests 
Falling liquid-film test (Teng, et al., 1987; Rao, et al., 1989 and Pimienta, et 
al., 1990) is one of the perfusion tests measuring the adhesion of particulate 
formulations. It involves placing the test material onto a section of excised stomach 
or intestine, mounted on an inclined platform and washing it with simulated stomach 
or intestinai solutions . The eluted particles are collected and quantified . The 
percentage of the particles adhering to the tissue is determined and used as an 
index of bioadhesive strength. 
Another perfusion technique is similar to the falling liquid-film test except that 
an entire segment of intestine is used rather than a part of the intestine. The radio-
labeled bioadhesive formulation is allowed to interact with the tissue for a period of 
time and then the perfusion is commenced . The radioactivity of the eluted samples 
is determined, which is used as an index of bioadhesion (King, et al., 1991 ). 
1.5.1.3. Rheological tests 
Rheological evaluation of mucus and polymer mixtures gives information on 
the extent and magnitude of interaction between the two, since the increase in 
viscosity resulting from mixing the two has been claimed to correlate with 
bioadhesion (Allen, et al., 1986; Hassan, et al., 1990). As with other experimental 
techniques, here also the in vitro - in vivo correlation is questionable. Besides the 
methods mentioned above there are other methods which have been investigated. 
Some methods such as the fluorescent probe technique (Park, et al., 1984) and the 
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colloidal gold technique (Park, 1989) do not bear much resemblance to bioadhesion 
within the Gl tract and will not be discussed here. 
1.5.1.4. Cell culture study 
Conducting studies to evaluate the in vivo oral absorption of test substances 
is expensive, time consuming and labor Intensive. Use of various epithelial cell lines 
as model membranes to study drug absorption is well accepted in the scientific world 
for preliminary screening of drugs and excipients since the results obtained are close 
to in vivo tests (Brayden, 1997). One could choose human cell lines to mimic human 
conditions to study aspects covering toxicity, absorption, mechanism of transport of 
the compounds, etc .. 
1.5.1.4.1. Cytotoxicity study 
Cell lines can be used to screen a preliminary cytotoxicity of the test 
compounds. Assays for cell viability (e.g. the MTT-transformation, the release of 
Lactate Dehydrogenase, Propidium Iodide Staining and Trypan blue test, etc.) and 
transepithelial electroresistance (TEER) can be used to assess the cytotoxicity of the 
compounds (Anderberg, et al., 1992 and Werner, et al., 1996). These results can 
be used as predictions for further studies to be done in animal models. 
1.5.1.4.2. Drug transport study 
Cell lines such as Caco-2 and HT29 have been suggested for screening drug 
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absorption at the early stage of drug development. Several advantages of applying 
them to pre-clinical studies have been suggested by many investigators including , 
the fact that they are human original, provide a high degree of reproducibility and a 
means of rapid assessment of the permeability of a drug ( Hilgers, et al., 1990; 
Wilson , et al., 1990; Hillgren, et al., 1995 and Sattler et al. , 1997). Drug transport 
study is carried out using either Transweii'IO', insert plates or modified Us sing diffusion 
chambers. Drug candidates are usually added to the donor compartment in the form 
of a radio-labeled or fluorescent molecule and detection is made by sampling both 
donor and receiver compartments to determine the amount of the drug transported 
across the monolayers. 
1.5.1.4.3. Mechanisms of transport study 
Many researchers have used the different cell lines to decipher the 
permeation pathway of a specific candidate compound across the epithelium. The 
transport of paracellular tight junctional markers such as 14C-mannitol or the TEER 
are usually used to monitor the tight junction of the epithelium. Apparent 
permeability coefficient (Papp) for 14C-mannitol of about 0.8-2.5 X 1 o-7 em/sec, and 
TEER of about 250-600 0 cm2 , indicate intact epithelial tight junctions. If the flux of 
a drug candidate is found to be unsaturable, equal in both the donor and receiver 
sides, pH independent, and cause no effect on the flux of 14C-mannitol or on the 
TEER, it indicates that the absorption mechanism of the drug is passive and 
transcellular. Agents causing a reversible increase in the flux of 14C-mannitol with 
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an associated drop in TEER suggest that the tight junctional paracellular passive 
pathway may play a role in its permeation. If the flux of the agent follows an active, 
carrier-mediated pathway, then the concentration in the donor side is found 
saturable, pH dependent, and there is an unequal net flux in both directions 
(Brayden. 1997). 
1.5.1.4.4. Caco-2 cell line 
Caco-2 cell line is the most popular commercially available human intestinal 
cell line for drug absorption studies . The cells were derived from a human colonic 
adenocarcinoma which differentiate after 15 to 20 days on polycarbonate filters to 
express many carriers of the small intestinal villi such as those for dipeptides. bile 
acids and Vitamin B 12. It has been widely used to study drug transport mechanisms 
(Artursson. 1990b and 1990c; Thwaites, et al., 1996; Rubas. et al., 1996 and 
Yamashita, et al., 1997) as well as absorption enhancement (Anderberg, 1992, 
1993; Schipper. et al., 1996 and Werner. et al., 1996). Caco-2 monolayer has also 
received considerable attention from the pharmaceutical industry because the 
correlation between drug permeability on Caco-2 monolayer and in vivo drug 
absorption is very high (Artursson, et al., 1991 ). Yamashita et al (1997) provided a 
theoretical rationale illustrated in Figure 1 for using the cultured monolayer system 
to predict in vivo drug absorption. The jejunal membrane has a villous structure that 
increases the effective surface area of absorption. Drugs can enter the blood 
circulation in vivo, just after crossing the epithelial absorptive cell layer from 
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capillaries in the lamina propria of the villi (Trier, 1981 ). ln contrast, in vitro 
permeation needs the diffusion of drugs from the mucosal to the serosal side of the 
membrane through the villi. This simple concept shown in Figure 1 is applicable not 
only to Caco-2 monolayer, but also to other monolayer systems and is very 
important when considering differences between the in vitro permeation and the in 
vivo absorption of drugs. 
In our study, Caco-2 cell monolayer was used to carry out transport study to 
investigate the effect of the alginate and pectin on enhancing the permeability of the 
epithelial membrane. 
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Figure 1. Schematic representation of in vitro permeation and in vivo 
absorption of drugs 
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1.5.2. In vivo test methods 
1.5.2.1. Bioavailability studies 
Some research groups have investigated the bioavailability of bioadhesive 
dosage forms using animal models or human volunteers (Longer, et al., 1 985; 
Chickering Ill , et al., 1997 and Santus, et al. , 1997). The results are controversial 
because some were oppos1te to the in vitro results and some did not show the same 
extent of improvement as that shown in the in vitro test due to complications in the 
in vivo situations. Especially for oral administration route, biological variables such 
as Gl motility, mucus turnover, presence of endogenous materials (e.g. enzymes, 
electrolytes , bile salts) and exogenous materials (e.g . food, drink, drugs) are very 
difficult to mimic in an in vitro model. 
1.5.2.2. Measurement of residence time 
The three main techniques which have been used to measure the residence 
time of bioadhesives in vivo include gamma scintigraphy (Khoshla, et al., 1987; 
Santus, et al., 1997 and Jacques, et al., 1997), perfused intestinal loops (Lehr, et al.. 
1990 and 1991) and transit studies with radio-labeled dosage forms (Ch'ng , et al., 
1985; Ponchel, et al. , 1997 and Chickering Ill, et al., 1997). Although the in vivo 
techniques listed above may be able to indicate the prolonged retention of a BODS 
at a particular site, they do not necessarily correlate with clinical efficacy of the 
incorporated drug. Hence, the extent of drug absorption can not be predicted from 
transit studies alone. Pharmacokinetic data can be obtained in conjunction with 
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each of these techniques which will provide more complete information about the 
BODS. 
1.6. Bioadhesive candidates 
In our research project, initially we screened a number of polymers to make 
the final selection of the few polymers most suitable for our work. The following 
section describes the polymers selected for pre-screening. 
1.6.1. Alginate (ALG) 
ALGs are natural, non-toxic, polysaccharides found in the cell walls and 
intercellular spaces of brown seaweed. ALGs are necessary for plant growth in the 
sea to provide the plant with both flexibility and strength. They are widely used in 
food and pharmaceutical industries, such as disintegrant, tablet binder. 
thickening/stabilizing agents in mixtures and as gelling agents in confectionary. 
Recently they have been employed as a matrix for entrapment of drugs (Bod meier. 
et al., 1989 and Rubio, et al., 1994), macromolecules (Mumper, et al., 1994 and Kim. 
et al., 1992) and biological cells (Lanza, et al., 1995). ALG acid is a linear copolymer 
of P-0-mannuronic acid and a-L-guluronic acid linked by (1 - 4)-glycosidic bonds. 
When producing ALGs, uronic acid is converted into the salt forms mannuronate (M) 
and guluronate (G) (see Figure 2a). It has been shown that the G and M units are 
joined together in blocks. Three types of blocks may be found, homopolymeric 
blocks MM and GG, heteropolymeric sequentially alternating blocks MG 
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(Yotsuyanagi, et al., 1991 ). The different block types are shown in Figure 2b. 
Regions of G monomers in one ALG molecule can be linked to a similar region in 
another ALG molecule by means of calcium or other multivalent cations such as 
aluminum and zinc (Figure 3a). The calcium cations fit into the G structures like 
eggs in an 'egg-box' (see Figure 3b). This binds the ALG polymers together by 
forming junction zones, thus leading to gelling of the solution . ALGs contain various 
proportions of M and G monomers , and gel formation depends on this distribution. 
To form a gel by reaction with calcium, ALG needs to contain a sufficient level of G 
monomer and a certain proportion of G monomers must be available in a block. The 
ALG containing the highest GG-fractions possesses the highest ability to form gels. 
The viscosity of an ALG solution depends on the length of the ALG molecules, such 
as the number of monomer units in the chains. The longer the chains the higher the 
viscosity at similar concentrations. We used sodium ALG with medium viscosity in 
ou r study. 
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1.6.2. Chitosan 
Chitosans are biodegradable, high MW cationic polysaccharides. Industrially 
they are produced from chitin, the world's second most abundant biopolymer, by a 
deacetylation process involving alkaline hydrolysis. Chitosan has been used for a 
range of applications as diverse as for water purification. as a food ingredient and 
as a pharmaceutical excipient in oral drug formulations for the improvement of the 
dissolution of poorly soluble drugs or to obtain controlled drug release (Li, et al., 
1992 and Hou, et al., 1985). It has been previously shown that chitosan has a great 
potential as a nasal delivery system, facilitating the passage of large hydrophilic 
molecules such as salmon calcitonin and insulin, through the nasal mucosa into the 
systemic circulation (Ilium, et al., 1994a). The tests of in vitro tensile strength show 
that chitosan has a very strong adhesion strength (Smart, 1984 ). Cell culture study 
indicates that chitosan can improve the absorption of the drug significantly as an 
absorption enhancer (Schipper, et al., 1996). 
1.6.3. Poly-/-lysine (PLL) 
PLL, a lysine polypeptide or homopolymer, is cationic polysarccharide with 
adsorption characteristics on membranes. The chain length of the polymer depends 
on the method of preparation. PLL has been known to have ionic interaction with 
polyanions such as ALG. It has been used in the preparation of ALG-PLL-ALG 
microcapsules, and its primary function is to form a strong membrane complex to 
stabilize and strengthen the ionic hydrogel. 
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Due to its polycationic nature, PLL has been reported to stimulate endocytosis 
of different cell types (Duncan, et al., 1979 and Ginsburg, et al., 1984). Literature 
data shows that PLL is immunogenic. Therefore, ALG-PLL-ALG microcapsules 
have the outer coating of ALG (PLL-ALG) to neutralize the non-reacted PLL and 
generate a negatively charged surface to avoid attachment of cells to the capsule 
membrane. This is expected to mask the unwanted immune iesponses of PLL. 
Shimi et al ( 1991) has examined the permeability, robustness and 
ultrastructure of ALG-PLL-ALG microcapsule made by PLL of different MW. The 
results indicated that PLL of low MW produced a relatively permeable and robust 
membrane whereas the high MW produced capsules with the reverse 
characteristics. A MW of 22,000 appears to be optimal in forming robust capsules 
which are relatively impermeable to high MW species such as immunoglobulins. 
Based on these reports, we selected the PLL with low MW (22,000) for our work. 
1.6.4. Pectin (PEC) 
PEC is a heterogeneous polysaccharide composed mainly of galacturonic 
acid and its methyl ester linked by a (1 -4) glycosidic linkage. It is nontoxic and used 
in many foods and confectionaries. It is resistant to gastric and intestinal enzymes 
(Sandberg, et al., 1981 ), but it is almost completely degraded by the colonic bacterial 
enzymes to produce a series of soluble oligogalacturonates (Cummings, et al., 1979 
and Englyst, et al., 1987). It is isolated from plant cell walls by a number of 
processes to produce PEGs with varying degrees of methoxylation. PEGs with high 
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degrees of methoxylation (HM) are poorly water-soluble. However, PECs with low 
degrees of methoxylation (LM) are more water-soluble and can be cross-linked by 
divalent cations. most commonly calcium. to produce an insoluble pectate gel. We 
used PEC with LM for our study. PEC has been recently used as a matrix for oral 
sustained release tablet and as a carrier for colonic drug delivery due to its 
prolonged retention at colon (Ashford, et al ., 1993b ). 
In our study we have used ALG as the core material for preparing drug-
loaded particulates. The hydrogel structure of calcium-ALG is fairly labile in the 
presence of monovalent cations, and the gel structure could be strengthened by 
using different compositions of ALG, calcium ion concentrations, gelation time etc. 
(Bod meier, et al., 1993; Kikuchi. et al.. 1997). Attempts to strengthen ALG 
particulates by complexing with cationic chitosan (Murata, et al., 1996) or PLL (Thu, 
et al. , 1996) have also been reported in the literature with varying degree of success. 
However, all these attempts only improved the release profiles of the drug from ALG 
particulates marginally. The difficulty in sustaining drug release is more for aqueous 
soluble drugs and those with smaller molecular weights, such as theophylline, 
acetaminophen and chloramphenicol (0stberg, et al., 1994 ). We aimed to develop 
a novel bioadhesive particulate system, using ALG with the help of PLL and PEC 
strengthening the partiuclates, to allow controlled release of small molecular weight 
drugs from the particulates. 
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1. 7. Model drugs 
Conventional drug with molecular weight less than 500 were chosen for this 
project. The three model compounds chosen (Figure 4) had a wide range of 
solubility to represent a wide range of compounds available in the market. 
1. 7 .1. Theophylline 
Theophylline is widely used in the treatment of asthma and other respiratory 
diseases. It has a narrow therapeutic window, and it is rapidly absorbed and 
eliminated. These attributes make theophylline a good candidates for sustained 
release. It has a solubility of 8.8 mg/ml (Robinson, et al., 1986). 
1. 7 .2. Chlorothiazide 
Chlorothiazide, a diuretic and antihypertensive drug , is slightly soluble in 
water; 400 mg/L at pH 4 and 650 mg/L at pH 7. Some research data suggests that 
the absorption of chlorothiazide from the Gl tract in humans may be saturable or 
site-specific (Longer, et al., 1985). 
1.7.3. Indomethacin 
Indomethacin, an anti-inflammatory drug, is frequently used in studies on 
hydrophilic matrix systems due to its poor water solubility. It is practically insoluble 
in water (the Merk Index) and represents the extreme in the solubility scale. 
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Figure 4. Structures of model drugs 
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2. RESEARCH OBJECTIVES 
The primary objective of the research is to prepare polymeric particulates that 
combine the advantages of particulates and bioadhesive drug delivery systems. To 
achieve the above objective the following secondary objectives were laid out: 
i) Develop an efficient method to prepare polymeric particulates using 
ionotropic gelation technique. 
ii) Explore the use of polymers which have both particulate forming property (by 
gelation technique) as well as bioadhesive property. 
iii) Study the in vitro release profiles of model drugs in the finally chosen 
polymeric particulates. 
iv) Study the in vitro bioadhesive property of the polymeric particulates . 
v) Evaluate the absorption enhancing effect of the polymers using cell culture 
experiments. 
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3. RESEARCH HYPOTHESES 
To achieve these research objectives. the following hypotheses are proposed : 
1. The merits ofbioadhesive and particulate technologies could be combined by 
selecting suitable polymeric materials and excipients to prepare particulates 
with bioadhesive properties. 
2. These particulates would also be suitable as sustained release dosage forms. 
3. Bioadhesive polymers would be able to adhere to mucus layer and increase 
the permeability of the epithelium. 
4. Due to their large molecular weight, polymers themselves are not likely to be 
absorbed and to produce undesired systemic effects. 
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4. MATERIALS AND METHODS 
4.1. Materials 
4.1.1. Chemicals and equipments 
Sodium alginate (suppliers' specification: viscosity of 2% solution at 25°C, 
3500 cps), chitosan (Supplier's specification: minimum 85% deacetylated), poly-/-
lysine hydrochloride (MW: -22,000/-48,000 Da), pectin as a potassium salt (degree 
of esterification: 28%), calcium chloride (CaCI 2 ), tripolyphosphate, Tween 20, glass 
beads (700-1,200 ~tm), mannitol, theophylline. chlorothiazide. indomethacin. 
hydroflumethiazide, Dulbecco's Modified Eagle's Medium (OMEM. with 4 .5g/L 
glucose), Non-essential amino acids (NEAA) and Trypsin (0.25%)-EDTA (1 mM) 
were all purchased from Sigma Chemicals, MO. USA. Fetal calf serum (FCS). 
penicillin-streptomycin (5.000 I. U./ml and 5,000 ~tg/ml) and sodium bicarbonate 
solution (7.5%, w/v) were obtained from Gibco BRL. Life Technologies, NY. USA. 
Concentrated hydrochloride acid (HCI ), ammonium chloride, sodium phosphate 
monobasic, potassium phosphate monobasic and potassium phosphate dibasic 
were purchased from Fisher Scientific Co., NJ, USA. Scintillation cocktail (Formula 
989®) was purchased from Packard Instrument Company Inc. CT. USA. Methanol 
and acetonitrile were of HPLC grade and purchased from Fisher Scientific Co., NJ, 
USA. Deionized water was obtained using the Barnstead Nanopure II system (MA, 
USA). 
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A homogenizer (Brinkmann Instruments Company, Switzerland)was used to 
mix the dispersions, Corning stirrer plate and magnetic stirrer (Fisher Scientific Co., 
NJ, USA) were used for agitation and Accumet8 pH Meter 10 (Fisher Scientific Co., 
NJ, USA) was used to precisely measure the pH value of the buffer solution . Freeze 
dryer (Labconco Corp., MO, USA) was used during the freeze drying procedure. A 
custom-designed artist airbrush (Paasche, CA, USA) was used to create a spray of 
polymer solution for the preparation of microspheres. A custom made tensiometer 
was used to measure the in vitro tensile strength . A humidity chamber was applied 
to offer an environment with high humidity. 
Water-jacketed incubator (lsotemp® Incubator Model 546, Fisher Scientific 
Co., NJ , USA) was employed to provide suitable environment for cells growth. Hund 
Wetzlar Wilovert® microscope (Wetzlar/Nauborn, Germany) and Hemacytometer 
(Hausser Scientific, PA, USA) were used for cells counting . Tissue culture flasks 
and pipettes were purchased from Fisher Scientific Co., NJ , USA. CostarTranswell® 
6-well plate inserts (pore size 0.4~Lm, Costar, MA, USA) were used for transport 
study. 
4.1.2. Instruments 
A liquid scintillation counter (Beckman LS 5000 TO, CA, USA) was used to 
measure radioactivity of 14C samples. A USP type I (basket) dissolution apparatus 
(Vanderkamp 600, Vankellndustries Inc. NJ, USA) attached to a fraction collector 
and a programmable dissolution sequencer (Vanderkamp model 10, Vankel 
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Industries Inc. NJ. USA) was used for in vitro release studies. A Beckman DU® -70 
spectrophotometer was used to measure the absorbance of the model drugs. 
Computerized image analysis (BIOQUAN~ system IV. USA) was performed to 
analyze the particulate size and scanning electron microscope (Hitachi S570 SEM, 
Japan) was operated to obtain the micro-structure of cross-section of the 
particulates. 
4.1.3. Radioisotope 
14C-mannitol (specific activity: 50 mCi/mmol, 0.25~tCi/mL) in ethanol solution 
was purchased from Sigma Chemicals. MO. USA. 
4.1.4. Cell line 
The Caco-2 cell line was obtained from American Type Culture Collection 
(MD, USA) at passage 17 and used for transport study. 
4.1.5. Animals 
Male Sprague Dawley rats weighing between 250g - 350g (Animal Care 
Center, Memorial University of Newfoundland, NF, Canada) were used for obtaining 
parts of the Gl tract for in vitro bioadhesive property tests. Plasma from the healthy 
rats was used for the preparation of the calibration curve of chlorothiazide in HPLC 
analysis and validation of the analytical procedure. 
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4.2. Methods 
4.2.1. Preparation of particulates 
4.2.1.1 Preparation of ALG particulates 
The method to prepare ALG particulates was adopted from Bod meier's work 
(1989) and changed to suit our need. A solution of sodium ALG (1.5%) wiV) was 
prepared in deionized water. The model drug was dispersed in the sodium ALG 
solution using a homogenizer (-1000 rpm). Then 20 ml of the dispersion, 
containing about0.4 g model drug, was added drop-wise using a disposable syringe 
(# 20 gauge) into 50 ml gently agitated aqueous CaCI2 solution (2% w/v). After 
allowing 10 min for gelation, the particulates were harvested and rinsed with 
deionized water to remove loosely adhered drug molecules. The ALG particulates 
were then dried using a freeze dryer without any pre-cooling step. Remaining traces 
of moisture were removed by desiccating under vacuum for at least 48 h. A few test 
samples were also air dried for comparison with the freeze dried products. 
4.2.1.2. Preparation of chitosan particulates 
The method to prepare chitosan particulates was also adopted from 
Bod meier's work (1990). A chitosan solution (1% w/v) was prepared in diluted acetic 
acid (1 %, v/v). The model drug was dispersed in the chitosan solution using a 
homogenizer. Twenty ml of the dispersion was added drop-wise using a disposable 
syringe(# 20 gauge) into 50 ml gently agitated tripolyphosphate solution (2%, w/v). 
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After 30 min gelation , the particulates were harvested and rinsed with deionized 
water to remove loosely adhered drug molecules. The particulates were then freeze 
dried without any pre-cooling step. Remaining traces of moisture were removed by 
desiccating under vacuum for at least 48 h. 
4.2.1.3. Preparation of ALG and chitosan microspheres 
A laboratory method to produce microspheres was developed using an artist 
airbrush . This method allowed to produce microspheres of any size by properly 
adjusting the air pressure and nozzle sizes. Mostly, we used nozzle size 3 (diameter 
1 mm) at the air pressure of 4-5 psi. The dispersions of sodium ALG or chitosan 
containing model drug described above were sprayed into either CaCI2 (2% w/v) or 
tripolyphosphate (2% w/v) solution. The gelation time ranged from 5 to 15 min . The 
microspheres were filtered out and freeze-dried for 12 h. During the preparation of 
chitosan microspheres, 0.5% Tween 20 was added to the tripolyphosphate solution 
to prevent agglomeration of microspheres. 
4.2.1.4. Preparation of ALG-PLL particulates 
We attempted to prepare ALG-PLL particulates by two different methods 
which were described below. 
4.2.1.4.1. Method of preparation of ALG-PLL I particulates 
The procedure was essentially similar to that of ALG particulates described 
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above (3.2.1.1.) with an additional step where the ALG particulates were coated with 
a PLL solution (0.1% w/v). Essentially 20 ml sodium ALG solution (1.5% w/v) 
containing the dispersed model drug were added drop-wise to 50 ml CaCI 2 solution 
(2%, w/v) and allowed to form temporary gel for 10 min. The particulates were 
harvested and resuspended in PLL solution (0.1 %. w/v) for 6 min to allow cross-
linking to occur between ALG (anionic) and PLL (cationic) and form a permanent 
layer. Thereafter, the particulates were filtered out. washed with deionized water 
and then suspended in 20 ml sodium ALG solution (0 .05% w/v} with gentle agitation 
for 4 min which reacted with any excess PLL at the outface of the particulates . The 
ALG-PLL I particulates were washed twice with deionized water and freeze-dried for 
24 h as described above. A few test samples were also air-dried for performing a 
comparative evaluation. 
In this study, we used PLL with a mean MW of- 22,000 in all cases except 
one where MW - 48,000 was used. Particulates prepared with the two MW PLL 
were compared with respect to their in vitro release profiles. 
4.2.1.4.2. Method of preparation of ALG-PLL II particulates 
At first, the CaCI 2 solution (2% w/v) was mixed with PLL solution (0.1% w/v). 
then sodium ALG dispersion (1.5% w/v) was added drop-wise into this mixed 
solution and gelated for 1 0 min to form the temporary gel particulates. The following 
steps are similar to those of ALG-PLL I particulates. Briefly, ALG particulates were 
suspended in PLL solution (0.1 %, w/v) for 6 min, then filtered out, washed with 
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deionized water and resuspended in sodium ALG solution (0.05%, w/v) for 4 min to 
neutralize any excess PLL at the surface. Finally these particulates were freeze 
dried. 
4.2.1.5. Preparation of ALG-PEC-PLL particulates 
The preparation was similar to that of ALG-PLL I particulates with a slight 
modification. In this procedure, firstly, 1.5% (w/v) of sodium ALG and 3.7% (w/v) of 
PEC were dissolved in deionized water, then the model drug was dispersed in the 
polymer solution using a homogenizer. The rest of the steps followed the 
preparation of ALG-PLL I particulates. Briefly, twenty ml of the dispersion was 
added drop-wise into 50 ml CaCI 2 solution (5%, w/v) to form the gel particulates for 
20 min, then the particulates were suspend in 15 ml PLL solution (0.1 %, w/v) for 6 
min . After washing with deionized water, they were resuspended in 20 ml sodium 
ALG solution (0.05%, w/v) for 4 min. Finally the particulates were freeze dried. 
Besides, during the preparation of ALG-PEC-PLL particulates, for some 
batches of theophylline loaded particulates the gelation time was 10 min. which were 
prepared to compare the in vitro release profiles with those prepared with 20 min 
gelation time. 
4.2.2. Particle size analysis 
The mean diameter and the size distribution of the dried and resuspended 
microspheres were determined by computerized image analysis. The freeze-dried 
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ALG and chitosan microspheres were suspended in phosphate buffer (pH 6.0) and 
dilute HCl (pH 1.0), respectively, soaked for 10 min and subjected to image analysis. 
Parameters such as periphery and the longest diameter were determined. 
4.2.3. Scanning Electron Microscopy {SEM) 
SEM was performed to characterize the cross-sectional view of the 
particulates in order to study the effects of the polymers and drying techniques. 
Cross-sections were obtained by cutting the particulates with a razor blade. The 
samples were then coated with gold-palladium for 70 seconds under an argon 
atmosphere and observed with a scanning electron microscope. In this study. we 
measured five different types of the particulates: 1. ALG particulates (air-dried}; 2. 
ALG particulates (freeze-dried); 3. ALG-PLL I particulates (freeze-dried); 4. ALG-PLL 
II particulates (freeze-dried); 5. ALG-PEC-PLL particulates (freeze-dried}. 
4.2.4. In vitro release studies 
4.2.4.1. Preparation of dissolution test soi•Jtions 
Phosphate buffer (0.05M, pH 7.5 ± 0.1) were prepared by mixing 250 mL of 
KH 2P04 solution (6.8 gin 250 ml) and 190 mL 0.2 M NaOH . The pH was measured 
and if required, adjusted with 0.2 M NaOH. The final volume was made up to 1000 
ml with deionized water. 
The 0.1 M HCI (pH 1.0 ± 0.1) was prepared by diluting 6.25 ml of 
concentrated HCI acid (37%, v/v) to 1000 ml with deionized water. The final pH 
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was determined using a pH meter. 
4.2.4.2. Dissolution tests 
The release studies were performed using a USP Type i (basket) dissolution 
apparatus attached to a fraction collector and a programmable dissolution 
sequencer. The stirrer speed was set to 120 rpm and the thermostat controlled 
water bath was set to 37 ' C. In this study, we used two different dissolution fluids. 
0.1 M HCI (pH 1.0 ± 0.1) and phosphate buffer (0.05M, pH 7.5 ± 0 .1 ). The total 
volume of the dissolution fluid was 900 ml. Drug-loaded particulates weighing 
between 40 and 100 mg (depending on the type of model drug) were placed in the 
basket. Dissolution test was performed over 8 h. Five mL of dissolution fluid was 
sampled at predetermined time intervals, viz., 15 min, 30 min. 45 min. 1 h. 1.5 h. 2 
h, 3 h. 4 h. 6 h, 8 h. The sample volume was replenished with fresh dissolution fluid 
after sampling. In order to determine the total content of the drug in the particulates, 
we also took the samples at 24 h and 72 h when the dissolution medium was 
phosphate buffer (pH 7. 5 ± 0.1 ). All experiments were performed in triplicate and 
the mean cumulative % of drug released ± SD are reported. 
4.2.4.3. Analysis of the model drugs 
Standard solutions of the test compound were prepared in phosphate buffer. 
After scanning the solutions, the Amax were selected for analysis . These values were 
272 nm for theophylline, 294 nm for chlorothiazide and 266 nm for indomethacin. 
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Standard curves were prepared by plotting UV absorbance vs. concentrations of the 
standard solutions . 
The test samples were measured either directly or after diluted with suitable 
dissolution medium such as 0.1 M HCI (pH 1.0) and phosphate buffer (pH 7.5). The 
amount of drug released was quantified spectrophotometrically from the standard 
curves. 
4.2.4.4. Drug content 
The cumulative amount of drug dissolved after 72 h of dissolution in 
phosphate buffer (pH 7.5) was taken as the total amount of drug in the particulates . 
All the three particulates. ALG, ALG-PLL and ALG-PEC-PLL, were observed to 
completely disintegrate after 48 h of dissolution, and hence, 72 h was considered as 
the adequate time period to release all the encapsulated drugs. 
4.2.5. Determination of bioadhesive strength 
4.2.5.1. Preparation of isolated rat stomach and jejunum 
Unfasted male Sprague Dawly rats (250-350 g) were sacrificed using an 
overdose of urethane. As for tensile strength test, the jejunum was cut and kept in 
phosphate buffer solution (pH 6.0) and used within 4 h of sacrifice. Before the test, 
the jejunum (2 .5-3 em) was cut longitudinally, gently washed with phosphate buffer 
and mounted on a platform to expose 2 cm2 of tissue. As for falling liquid film test, 
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the stomach and jejunum were cut and stored in 0.1 M HCI and phosphate buffer 
(pH 6.0), respectively, and used within 2 h of sacrifice. Before the test, the stomach 
and jejunum (5-7 em) were cut open longitudinally, emptied of food and washed with 
0.1 M HCI (20 ml/min) and phosphate buffer (pH 6.0, 20 ml/min), respectively, until 
they were clean. Pieces (5-7 em) of jejunum or stomach were placed on one half 
of a longitudinally cut rubber tube (2 em diameter) with the help of pins. They were 
used as the bio-surface for the in situ test. 
4.2.5.2. In vitro tensile strength test 
A custom made tensiometer (Figure 5) was used to measure the tensile 
strength of polymer candidates when brought in contact with rat intestinal mucosa. 
Freshly excised rat jejunum was used as the bio-surface for this test. Glass slides 
(22X22X0.15 mm) were coated with the polymer solution and air dried to form a thin 
film. The weight of the glass slide was counterbalanced with a plastic container 
having requisite amount of water on the other side . Then the polymer film was kept 
in close contact with the tissue mounted on the platform by placing a 2 g weight on 
the glass side of the glass slide for 5 min. Just before the measurement of tensile 
strength, the weight was removed. Water was added drop-wise (4.5 ml!min) to the 
container with the help of a peristaltic pump that ensured a smooth flow of water and 
avoided any jerky movement. The pump was switched off as soon as the polymer 
film got detached from the tissue. The experiment was repeated five times to 
determiile the average tensile strength, and each time a fresh piece of mucosal 
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tissue and a new polymer covered glass slide were used. (lehr, et al. , 1990; Smart 
1991 and Parodi, et al., 1996) 
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Figure 5. Schematic diagram of the modified tensiometer used to test the tensile 
strength of the bioadhesive polymers: a) disk; b) platform; c) stopper; 
d) plastic container; e) balance; f) pump. 
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4.2.5.3. In situ falling liquid film test 
This procedure was adopted from Rango Rao and Buri's method (1989). 
Isolated rat jejunum and stomach pieces were used as the bio-surface to test the 
bioadhesive strength of the test particulates. Silica coated glass beads (700-1, 100 
~lm) were used as the control samples. A humidity chamber (80% RH) was 
prepared by saturating it with a saturated solution of ammonium chloride at room 
temperature (25 ± 1 °C). About 50 mg of test samples were placed on the piece of 
tissue (stomach or jejunum) and incubated for 20 minutes in the humidity chamber. 
This procedure allowed the particulates to hydrate and interact with the mucosal 
surface of the gut. Then the tissue-particulate assembly was placed on the plastic 
support, fixed at an angle of 45° (Figure 6). A rubber tube connected to a peri~ialtic 
pump was placed about 1 em above the tissue sample to obtain an even flow of 
liquid . The particulates were washed by pumping either dilute HCI (for stomach 
tissue) or phosphate buffer solution (for jejunum tissue) at 30 mllmin. The 
percentage of the particulates retained on the test tissue was used as an index of 
the bioadhesive property of the particulates. It was determined by collecting the 
washed particulates and counting them. 
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peristaltic pump 
.. 
- - -
reservoir containing the washing solution 
plastic support 
~pt.,~--- tissue (stomach or jejunum) 
particulates 
-- .. _-:. -----~ 
receiver for collecting the washed particulates 
which are quantified to determine bioadhesive property 
Figure 6. Schematic diagram of the assembly used to test the bioadhesion of 
the particulates (Ranga Rao and Buri, 1989) 
·61-
4.2.6. Transport studies using Caco-2 monolayers 
4.2.6.1. Cell cultures 
Caco-2 cells were cultivated with completed DMEM (supplemented with 10% 
FCS, 1% NEAA, 2% sodium bicarbonate and 1% penicillin-streptomycin) and 
incubated in tissue culture flasks in an atmosphere of 5% C02 and 95% air at 37 :c . 
The medium was changed every 48 h. The confluent cells were passed by using 
trypsin-EDT A to detach the cells from the flasks. Cells with passage number 26-29 
were used for the experiments. 
4.2.6.2. Preparation of Caco-2 monolayer 
Initially, confluent Caco-2 cells (passages 26-29) were harvested with trypsin-
EDT A and cultivated on tissue culture treated polycarbonate filters in Costar 
Tran~well® 6-well plate inserts at a seeding density of 3 X 105 cells/well . Completed 
DMEM was used as culture medium. The medium was added to both the donor (1 .5 
ml) and the receiver compartment (2.5 ml), and it was replaced every 48 hours. 
The cell were incubated in an atmosphere of 5% C02 and 95% air at 37 :c . The 
cells were used for the transport study between 21-23 days after seeding. 
4.2.6.3. Preparation of polymer solutions 
For the transport experiment, two different test samples were prepared. One 
contained 1% ALG, 1% PEC and 0.1% mannitol in DMEM, and the other one 
contained 1% ALG, 2% PEC and 0.1% mannitol in DMEM. Just before the addition 
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of the polymers, twenty Ill of radio-labeled 14C-mannitol alcohol solution (Specific 
activity: 0.25 ~tCi/mL) was added into 40 ml of the above solution as a tracer to 
facilitate the analysis by liquid sintillation counting (LSC). 
4.2.6.4. Transport of 14C-mannitol across Caco-2 monolayers 
Caco-2 monolayers were used to perform transport studies in this experiment. 
During 21-23 days after seeding, the Caco-2 cells became confluent and totally 
differentiated with villi and carriers. The morphological development in the cells 
were noted primarily based on the observation of the monolayers under microsocpe. 
The old medium was removed from both the donor and the receiver compartments 
of the Transwelle inserts. Two ml fresh completed DMEM was added to the 
receiver compartment and 1.5 ml polymer solution sample was add to the donor 
compartment of each well. The control solution only consisted of 0.1% (w/v) 
mannitol and the tracer in DMEM without the polymers . Transport studies were 
performed over 180 min in the incubator. Samples (1 OOuL) were taken from the 
receiver compartment at 0 min, 30 min, 60 min, 90 min, 120 min, 150 min, 180 min. 
The volume removed from the receiver compartment was replenished with fresh 
completed DMEM. Samples (100,ul) were also taken from the stock polymer 
solutions to determine the total radioactivity. To each of the test samples, 5 ml of 
scintillation cocktail was added before determining the disintegrations per minute 
(dpm) using the liquid scintillation counter. The background radioactivity was 
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measured using 100 ul of completed DMEM. All of the samples were counted at 
a window setting for standard 14C with a preset time of 15 min. The background 
radioactivity was subtracted from each sample reading. 
4.2.6.5. Calculation of apparent permeability coefficients (P app) 
The Papp {em/sec) were determmed using the following equation (Artursson, 
1990): 
~a 
papp = 
~t X 60 X A X C0 
Where ~aht is the permeability rate (dpm/minute), 
C0 is the initial concentration of mannitol in the donor compartment (dpm/ml) 
A is the surface area of the membrane (4.71 cm2 ). 
In order to observe the effects of the test samples on permeability as a 
function of time, the Paoo values were calculated for each time point separately. All 
experiments were carried out in triplicate and the mean Paoo ±SO are reported. 
4.2.7 Statistical evaluation 
In this study, Sigmaplot® 4.0 and SPSS 7.5 for Windows program were used 
to analyze the data. All data are expressed as the mean ± SO. Statistical 
differences were determined using one-way ANOVA and Bonferroni t-tests for 
multiple comparisons. Differences between group means were judged with p = 0.05. 
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5. RESULTS AND DISCUSSION 
5.1. Bioadhesive particulates 
The important features of a good drug delivery system include versatility to 
carry drugs with different physicochemical properties. simplicity of the method of 
preparation and feasibility for mass production. We have attempted to bear these 
factors in mind while formulating the ALG-based particulates. With the use of 
organic solvents for preparing particulates such as polylactide glycolide 
microspheres, there are two main problems: toxicity due to the residual organic 
solvents, and instability of certain drugs, especially those belonging to the class of 
peptides and proteins (Cleland, 1 996). Our method to prepare drug-loaded 
particulates involves only aqueous solvents. Although at this initial stage of 
development we have used conventional drug molecules as model compounds, the 
technique is also expected to be applicable to peptide and protein drugs. Although 
the samples for our experiments were prepared using a syringe technique, micro-
drops of the polymer solution can be sprayed using an air-brush spray device (Kwok 
et al. 1991 ). We have attempted this technique in our laboratory to successfully 
prepare microspheres which are 100-200 ~min size. Although the feasibility has not 
been checked, the technique seems to have potential for larger scale production. 
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5.1.1. ALG particulates 
The mechanism of ALG gelation with calcium ions is quite well understood. 
It is believed that junctions are formed by an interchain chelation of calcium ions 
between homopolymeric G-blocks . Above a certain threshold ALG concentration the 
gel strength increases in proportion to the square of the ALG concentration, and 
there is an indication of bimolecular mechanism for junction formation (Martinsen, 
et al., 1989). Therefore, the higher the concentration, the stronger the particulates. 
Different concentrations of CaCI2 and gelation times have also been studied to 
optimize the strength of ALG particulates . Martinsen's research group also 
investigated the effects of changing the concentration of CaCI 2 and of storing the gel 
particulates. Their results indicated that above a certain concentration of calcium 
ions (depending upon the type of ALG) and above certain storage times, the gel 
beads are quite stable with respect to changes in volume and strength. Other 
groups have reported the use of 1-1.5% CaCI 2 and 5 min gelation time for the 
preparation of ALG particulates due to the quick interaction between ALG and 
calcium ions (Bodmeier, et al., 1991; Shiraishi, et al., 1993 ). Here, we used 2% 
CaCI 2 solution and 10 min gelation time in most of our experiments. 
We tried different concentrations of sodium ALG solution to prepare ALG 
particulates by syringe technique. Two percent (w/v) sodium ALG solution was very 
viscous, thereby it was very difficult to push the solution through the narrow syringe 
needle. In addition, it was difficult to disperse the drug powder homogeneously in 
the solution. A concentration of 1.5% (w/v) sodium ALG was found suitable for the 
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particulate preparation by syringe technique. 
The spherical particulates were formed spontaneously as soon as the sodium 
ALG drop touched the CaCI 2 solution. Freshly prepared particulates were spherical 
and flexible. It has been shown earlier that the elasticity of ALG gels was energetic 
rather than entropic because the stiff ALG chains were densely cross-linked with 
calcium ions (Smidsr0d, 1990). Multivalent ions such as calcium, exchange with 
sodium ions of sodium ALG solution to form calcium ALG gel. On placing the gel in 
a solution containing monovalent cations the reversible process takes place. 
resulting in the gel to sol transformation. Thus, the dried ALG particulates swell in 
aqueous solution and disintegrate in the presence of monovalent cations. As a 
result of this erosion, the encapsulated compound get released from the particulates. 
The release profiles will depend on the strength of the gel and the rate of particulate 
erosion (Shenouda, et al., 1990). 
5.1.2. Chitosan particulates 
Chitosan is a cationic polymer and can interact with anionic compound, 
tripolyphosphate, to form a hydrogel. The hydrogel is stable in aqueous solution 
containing monovalent cations, but disintegrates in acidic medium such as in the 
stomach. 
The shape of the chitosan particulates was not as spherical as that of ALG 
particulates. Some particulates even had small spikes. This was probably because 
the interaction between the cationic polymer and the anions was not spontaneous 
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enough, or maybe the droplets from the syringe were not totally spherical due to 
their high viscosity. Another drawback was that the particulates were very soft after 
gelation, and the longer gelation time did not make the particulates hard. We tried 
to increase the gelation time to 30 min and 1 h, and found no change in the 
hardness. The particulates could keep the spherical shape when they were in the 
solution, but became somewhat flat when filtered out and stuck to each other. Use 
of Tween 20 (0.5%) prevented interparticle sticking in the solution helped only 
marginally. Freeze drying seemed to alleviate the problems and the dried particles 
were spherical. 
Many studies have been done to investigate the potential use of chitosan as 
a particulate system (Bodmier, et al., 1990 and 1993). Although chitosan has a few 
desirable properties such as high in vitro bioadhesive strength and good permeability 
enhancement, we did not find it to be a suitable candidate in our study since it did 
not allow us to integrate polymers to take advantage from their individual properties. 
5.1.3. ALG microspheres and chitosan microspheres 
It has been reported that smaller sized particles could be prepared by using 
compressed air to spray the dispersion through a narrow nozzle, and the size of the 
microspheres could be controlled by using different nozzle sizes and air pressure 
(Kwok, et al., 1991 ). In our study, for both ALG and chitosan particulates, a spray 
technique by using an artist airbrush was developed to explore the possibility of 
obtaining smaller particulate size. We employed the size 3 nozzle to prepared the 
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ALG and chitosan microspheres at the air pressure of 4-5 psi, and the particle size 
ranged from 300 pm to 700 ~tm. However, the preparation procedure itself was 
fraught with numerous problems . It was very labor intensive and time consuming. 
Attempt to produce microspheres using the spray technique was cumbersome due 
to constant blocking of the outlet pore. Because of these difficulties, we did not 
pursue with ALG and chitosan microspheres further. Therefore, we prepared the 
particulates using syringe technique for the in vitro studies although the particle size 
was relatively large (d iameter- 2.5 mm). 
5.1.4. ALG-PLL I and II particulates 
In order to prepare particulate carriers which are resistant to degradation and 
able to improve drug release profiles, attempts were made to combine two or more 
polymers. Gel particulates composed of different negatively and positively charged 
polymers represent a type of drug delivery system that can be prepared without a 
tedious process . It should be possible to control the release of various drugs by a 
proper selection of these polymers , by modification of the gel matrix and by 
improvement of the gel preparation . Coating ALG particulates with PLL is reported 
in the literature (Uiudag, et al., 1993). In this work Uludag et al. have coated the 
ALG particulates externally to prolong the life of ALG particulates. PLL. which is 
positively charged, showed a very strong affinity to the negatively charged ALG. 
The difference between the ALG-PLL I particulates and ALG-PLL II 
particulates could not be observed by the size or the shape. We assumed that the 
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preparation procedure of particulates II would allow the inside cross-linking between 
ALG and PLL to occur when sodium ALG form the hydrogel, and this might improve 
the micro-structure of the particulates to make them stronger. This assumption has 
been proved by SEM photographs (please see section 4.3.3.). As predicted, 
although the ALG-PLL I particulates did not disintegrate for more than 24 h, there 
was no significant improvement in prolonging the release of the encapsulated drugs 
with low MW. While ALG-PLL II particulates had a more stable matrix due to the 
inside cross-linkings and improved drug release profiles (please see section 4.4.3.). 
It has been reported that PLL is immunogenic and high concentration of PLL can 
cause immunological toxicity in animal models (Thu, et al.. 1996). Although the 
ALG-PLL II particulates held promise with regard to improving the release profiles 
of the encapsulated drugs (please see Section 4 .5), we did not pursue with it further 
due to the high content of PLL which has potential of causing toxicity. 
5.1.5. ALG-PEC-PLL particulates 
In our attempt to improve ALG particulates, we now incorporated PEC in the 
particulates. PEC also forms hydrogel with divalent cations such as calcium. Ca-
PEC hydrogel is stable in the stomach and small intestine, but breaks down in the 
colon region in the presence of microflora. This property of Ca-PEC gel has been 
employed to coat tablets for colonic drug delivery (Puttipipatkhachorn, et al., 1997; 
Ashford, et al., 1993, 1994). To our knowledge both ALG and PEC together have 
not been tried in the preparation of particulates for obtaining sustained release of 
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drugs. An outer mask of PLL would serve the same purpose as in ALG-PLL 
particulates. 
Although both sodium-ALG and PEC are known to form hydrogels upon 
contact with calcium ions (Bodmeier, et al., 1991 and Ashford, et al., 1994), we 
observed that the ionotropic gelation was spontaneous for ALG while that for PEC 
took some time and the particulates did not assume a spherical shape. Therefore, 
we increased the gelation time to 20 min for the preparation of ALG-PEC-PLL 
particulates. We anticipated that the longer gelation time would ensure complete 
cross-linking between PEC and calcium ions. 
Formation of ALG-PEC-PLL particulates was as spontaneous similar to the 
formation of ALG and ALG-PLL particulates and the shape remained spherical. 
Hence, it seems that the presence of ALG is very much essential for spontaneity of 
ionotropic gelation and for the maintenance of a spherical shape of the particle . 
Besides, being polyanionic ALG also served as a template to bind to the polycation, 
PLL, which helped in prolonging the life of ALG particulates in aqueous solutions. 
Although the concentration of PLL in the particulates was low, a final coating of 
sodium-ALG was done to neutralize any unreacted PLL. This was done to minimize 
any unwanted immune responses to PLL, and also to provide a negative surface 
charge to the particulates that would allow them to bind to mucous membranes (Thu, 
et al., 1996). PEC was used as the co-core material and its ability to withstand 
degradation in gastric pH and the gut made the particles more robust. As a result 
the particulate's ability to sustain drug release was significantly improved. After 
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performing the initial in vitro tests for the various particulates, ALG with PLL and 
PEC were found most promising. Hence, from hereon. the results and discussion 
will mostly pertain to them. 
5.2. Gelation time 
Gelation time played an important role in the performance of the particulates. 
It affected the strength of the particulates, the drug loading and release profiles of 
the drugs. The effect of gelation time on release profiles of the drug is discussed in 
section 5.5.3. 
5.2.1. Strength of ALG/ALG-PEC-PLL particulates and gelation time 
As mentioned before, Martinson et al. (1989) has studied the relationship 
between the strength of the ALG particulates and the gelation time . The strength of 
the ALG particulates increased as the gelation time was increased up to certain 
point. Further increase in the gelation time did not make any significant difference 
in the particulate strength. Based on our study we determined that 10 min of 
gelation time was optimum for ALG and ALG-PLL particulates and 20 min of gelation 
time was optimum for ALG-PLL-PEC particulates. 
5.2.2. Drug loading efficiency and gelation time 
Drug loading depends on both the solubility of the drug and the gelation time 
allowed. Longer gelation time would lead to leaching of soluble drugs from the 
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particulates to the surrounding aqueous medium, thereby reducing drug loading. 
Hence, we kept the gelation time as short as possible. 
In our experiments, during the preparation of ALG and ALG-PLL particulates, 
the gelation time of calcium-ALG spheres was kept 10 min, while for those 
containing PEC it was kept 20 min. Twenty min gelation time was anticipated to be 
sufficient to allow PEC and calcium ions to cross-link completely. For soluble drugs 
gelation time was a major concern that would affect drug loading. Due to the 
relatively high water solubility, theophylline loaded ALG-PEC spheres were allowed 
only 10 min gelation time. The time allowed for the interaction between ALG and 
PLL were kept uniform in all the particulates in order to avoid interparticulate 
differences. 
The drug loading and encapsulation efficiency of the model drugs in the 
freeze-dried particulates are given in Table 3. Drug loading represents the 
percentage of the particulate that is occupied by the drug. For example. 22.4% of 
theophylline in ALG particulates indicates that 22.4% of the particle is the drug and 
the remaining 77 .6% is the polymer. The values, given within the brackets, are the 
encapsulation efficiency of the preparation procedure which indicate the percentage 
of the original drug that has been incorporated in the particulates. The gelation time 
for ALG and ALG-PLL particulates were 1 0 min and that for ALG-PEC-PLL was 20 
min. 
Although use of aqueous medium has its advantages (described in section 
5.1 ), one of the problems is the relatively lower drug-loading efficiency for the water 
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soluble drugs. This problem may be minimized by reducing the total contact time 
of the drug in the calcium chloride solution. The unloaded drug present in the left-
over calcium chloride solution may be salvaged by extracting with an organic 
solvent. such as chloroform or hexane. 
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Table 3. Drug loading and encapsulation efficiency of the model drugs in the different freeze-dried particulates 
%Actual drug loading (nncapsulation efficiency) 
ALG ALG-PLL(Iow MWt ALG-PLL(high MWt' ALG-PEC-PLL 
Theophylline 22.6 (41.8) 26.2 (48.1) 12.5 (36.6) 
Chlorothiazide 38.0 (77 .7) 45 .5 (92 .9) 23.4 (93.2) 
Indomethacin 34.3 (68.0) 46.7 (94 .1) 47 .0 (94.7) 21 .8(94 .1) 
1. PLL MW 22,000 Da; 
2. PLL MW 48,000 Da; 
The values outsides the brackets are actual drug loading and those within the brackets are encapsulation efficiencies of the model drugs; 
Gelation time allowed for ALG , ALG-PLL was 10 min, and for ALG-PEC-PLL was 20 min. 
From the results it is evident that for the most soluble drug theophylline, 
encapsulation efficiencies were the lowest. For the less soluble drugs chlorothiazide 
and indomethacin, they had similar drug loading and encapsulation efficiencies and 
their encapsulation efficiencies were higher than that for theophylline. Another 
obvious observation was that for theophylline increasing the gelation time from 10 
min (in the ALG and ALG-PLL particulates) to 20 minutes (in the ALG-PEC-PLL 
particulates) resulted in a significant decrease in encapsulation efficiency. However, 
for the less soluble drugs, chlorothiazide and indomethacin, the encapsulation 
efficiency remained unchanged . 
In summary, encapsulation efficiency is an important parameter that could 
be used to compare different preparation procedures. Drugs that are soluble in the 
medium of preparation (within this case is water) are more susceptible to the 
changes made in the process. 
5.3. Factors influencing the characteristics of the particulates 
5.3.1. Effect of drying techniques on physical characteristics of particulates 
The drying technique used in this study influenced the final shape and size 
of the particulates. Freshly prepared particulates were spherical and flexible . After 
freeze drying, the final particulates were white and spherical and could be flattened 
out rather than brittle. The dried particulates kept almost the same shape and there 
was no significant shrinkage in the size. The particulates prepared using a syringe 
(20 gauge) were about 2-3 mm in diameter. Those prepared by air-spray technique 
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were about 300- 700 ~tm in diameter. 
The air-dried particulates could not retain the spherical shape of the freshly 
prepared particulates, and shrank more than 50% in size. It has been reported that 
the higher the values of the L-guluronic acid content and the average length of the 
G-blocks, the lower the shrinkage of the ALG particulates (Martinsen, et al., 1989). 
The air dried particulates were irregular in shape, hard and more off-white than the 
freeze-dried particulates. However, they could swell up to about the same size as 
the freshly prepared ones (approximately 2-3 mm) when placed in an aqueous 
solution, especially in the presence of monovalent cations. 
The freeze-drying technique seemed superior with regard to retaining a 
spherical shape, size and color of the particulates. It would also be more suitable 
for drugs that are thermolabile and susceptible to degradation on prolonged contact 
with moisture since the drying occurs at sub-zero temperature and time taken is far 
less than air-drying. 
5.3.2. Effect of drying techniques on the micro-structures of the particulates 
The internal micro-structure of the particulates were observed using scanning 
electron micrographs of the particulates. The cross sections of freeze-dried 
particulates viewed under a scanning electron microscope showed numerous, 
honeycomb-like open cavities (Fig 8, 9, 10 and 11 }, as opposed to a less open and 
denser structure for the air-dried ones (Fig 7). This suggested that drying 
techniques played an important role in the micro-structure of the particulates. Water 
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inside the particulates helped in giving the particulates a spherical shape. In the 
freeze-drying procedure. the particulates were frozen very quickly at a freezing 
temperature(- -50 =c) before the water inside was drawn out of the particulates so 
that the spherical shape of the particulates was retained. The water droplets inside 
became icelets and were removed by sublimation,leaving behind numerous cavities 
inside. However, when the particulates were air-dried, the water inside evaporated 
very slowly and the particulates shrunk with it, giving it a denser and irregular final 
shape. 
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Figure 7. Scanning electron micrograph of the cross-sections of ALG 
particulates prepared by air-drying technique (Magnification X1 00) 
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Figure 8. Scanning electron micrograph of the cross-sections of ALG 
particulates prepared by freeze-drying technique (Magnification X35). 
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Figure 9. Scanning electron micrograph of the cross-section of ALG-PLL I 
particulates prepared by freeze-drying technique (Magnification X35) . 
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Figure 10. Scanning electron micrograph of the cross-sections of ALG-PLL II 
particulates prepared by freeze-drying technique {Magnification X~5). 
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Figure 11. Scanning electron micrograph of the cross-sections of ALG-PEC-PLL 
particulates prepared by freeze-drying technique (Magnification X35). 
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5.3.3. Effect of polymers on the micro-structures of the particulates 
Figures 8-11 show the SEM graphs of the freeze-dried particulates. The SEM 
graphs of the cross-sections of the particles were taken to observe the internal 
structures . There was a big cavity in the center of the ALG (Fig. 8) particulate. 
ALG-PLL I (Fig. 9) particuiates had relatively larger honeycomb-like cavities. The 
SEM graphs of the cross-section of ALG-PLL II (Fig. 1 0) and ALG-PEC-PLL (Fig. 
11) particulates were similar and looked denser. This could result in increasing the 
diffusional barrier for the encapsulated drugs in these two particulates. 
5.4. In vitro release profiles of drugs from particulates 
The three model drugs chosen, represented the wide range of 
physicochemical properties of conventional drugs presently. Theophylline is 
relatively soluble (8 .33 g/L), chlorothiazide is slightly soluble (0.4 g/L at pH 4 and 
0.65 g/L at pH 7) and indomethacin is practically insoluble in water. The drug 
release profiles were studied at two pH conditions, in 0.1 M HCI medium (pH 1.0 ± 
0.1) simulating the gastric condition, and phosphate buffer medium (pH 7.5 ± 0.1) 
simulating the intestinal condition. After initially screening different particulates, 
three particulates, viz., ALG, ALG-PLL and ALG-PEC-PLL, were chosen for the 
tests. The results of other particulates which were not of interest are not discussed 
further. ALG particulates were used as a relative control in the dissolution tests . 
Model drug loaded particulates were prepared for ALG, ALG-PLL and ALG-PEC-
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PLL and their dissolution profiles were studied in details . The release profiles of the 
three model drugs from the particulates at two pH conditions were plotted as 
cumulative %of drug released over a time period of 8 h and are shown in Figure 12-
21. The underlying fact in all the figures is the influence of drug solubility on the 
release profiles, the higher the solubility the faster the release (Theophylline > 
Chlorothiazide > Indomethacin). The dissolution time for releasing 50% and 90% 
drug, viz., t50. ~ and lg0 .. t0 , are given in Table 4. 
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Table 4. Dissolution half life, t!>u',. and t,,,_ of the particulates in acidic and alkaline media 
In 0.1 M HCI pH 1.0 
t w .. (h)± SD 
ALG ALG-PLL ALG-PEC-PLL ALG 
Theophylline 0.49±0.008 1.05±0.004 1.70±0.008 3.91±0.028 
Chlorothiazide 1.38±0.021 --- - -
Indomethacin --- ----- ---- - - -
" - " indicates that less than 50% of drug was released in 8 hours. 
In phosphate buffer pH 7.5 
t !>()""- (h)± so 
ALG ALG-PLL ALG-PEC-PLL ALG 
Theophylline 0.21±0.007 0.24±0.008 0.90±0.007 0.96±0.033 
Chlorothiazide 0.80±0.009 0.82±0.012 1.50±0.015 3.00±0.048 
Indomethacin 1.00±0.004 1.92±0.011 2.70±0.016 7.02±0.023 
I !ru"" (h) :t SO 
ALG-PLL ALG-PEC-PLL 
4.60±0.017 6.05±0.015 
·--- - - -
- --- --~·--
t !IO", (h)± SD 
ALG-PLL ALG-PEC-PLL 
1.32±0.028 3.50±0.015 
2.20±0.008 6.02±0.04 
8.10±0.014 9.21±0.013 
5.4.1. Standard curves for the model drugs 
The calibration cuNes for the model drugs were established . The relationship 
between the absorbance and the concentration were as follows: 
Theophylline: 
Chlorothiazide: 
Indomethacin: 
Abs =Cone. X 0.0563 + 0.00814 , r-2 = 0.9999; 
Abs =Cone. X 0.0342- 0.00044. ~ =0.9998; 
Abs =Cone. X 0.0506 + 0.0198. ~ = 0.9997. 
5.4.2. Drug release in acidic solution 
In the acidic solution there was minimal release of chlorothiazide and 
indomethacin . Only the very soluble drug, theophylline. was released from all the 
three particulates . ALG. ALG-PLL and ALG-PEC-PLL (Figure 12). The t50 •. ,, of 
theophylline from the three particulates were 0.49h, 1.05h and 1. 70h. respectively . 
The t90.,. also showed a similar trend (Table 4) viz .. fastest from ALG (3 .91 h). 
intermediate from ALG-PLL (4.6 h) and slowest from ALG-PEC-PLL (6 .05 h). 
Chlorothiazide being only slightly soluble in acidic medium (<0.4 g/L at pH 1 ), 
was released only to a small extent from the most permeable ALG particulates. Its 
t50% was 1.38 h (Table 4, Figure 13). However, in the 8 h study less than 50% of the 
drug was released from ALG-PLL and ALG-PEC-PLL particulates . For the poorly 
soluble drug indomethacin, the amount of drug released from all the three 
particulates were far less than their t50% values (Figure 14 ). No more than 3% of drug 
were released from both ALG-PLL and ALG-PEC-PLL particulates within the 8 h 
duration. 
-87-
We speculate that drug release occurs by both diffusion and erosion in the 
ALG particulates and primarily by diffusion in ALG-PLL and ALG-PEC-PLL 
particulates. ALG particulates are more fragile to break and release the 
encapsulated drugs. Hence, dissolution is fastest from ALG particulates, ALG-PEC-
PLL is more resistant to degradation in the acidic medium. This is primarily due to 
the presence of the pectin gel wh1ch 1s stable 1n ac1dic pH and diSintegrates oniy in 
the presence of microflora (Sandberg, et al., 1981; Englyst, et al.. 1987). As a 
result, drug release from ALG-PEC-PLL is primarily occuring by diffusional process . 
ALG-PLL is in the intermediate category. PLL affords some robustness to ALG 
particulates but can not prevent the degradation of calcium ALG inside. Since the 
ALG-PEC-PLL particulate retained its shape for a prolonged period and, released 
only a small quantity of the encapsulated drug in the acidic medium. it may be 
reasonable to speculate that the particulate will protect drugs which are susceptible 
to degradation in the acidic environment. But this has to be confirmed by conducting 
further experiments with acid labile drugs. 
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Figure 12. Cumulative release profiles of theophylline from different 
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5.4.3. Drug release in alkaline solution 
For theophylline t50. ,. from ALG, ALG-PLL and ALG-PEC-PLL particulates 
were 0.21, 0.24 and 0.9 h, respectively and the tg0. ,. were 0.96, 1.32 and 3.50 h. 
respectively (Table 4 ). As shown in Figure 15. plain ALG particulates, although 
somewhat stable in acidic pH conditions, were unable to control the release of the 
very soluble drug , theophylline beyond one hour. The release profiles of 
theophylline also showed a high burst effect; about 70% theophylline was released 
in15 minutes (Figure 15). Coating with PLL helped only marginally in prolonging the 
release of theophylline because the out layer formed by cross-linking ALG and PLL 
had very large pore size. The most significant difference was obtained by ALG-
PEC-PLL particulates where the lg0 .\, was 3.5 hours and the burst effect was 
significantly reduced. This could be attributed to the presence of PEC gel which is 
stronger and stabler than ALG gel in both acidic and alkaline solutions . 
Chlorothiazide and indomethacin had the similar trends (Fig 16 and 17). The 
t50. ,. of chlorothiazide from ALG and ALG-PEC-PLL particulates were 0.8 hand 1.5 
h, respectively, and their lg0% were 3.0 h and 6.02 h, respectively. The t50 • • of 
indomethacin from ALG and ALG-PEC-PLL particulates were 1.0 h and 2. 7 h, 
respectively, and their l,0% were 7.02 h and 9.21 h. respectively. The t50.,, of 
indomethacin from ALG-PEC-PLL was about 2.7 times longer than that from ALG, 
while its t90% was longer by 1.3 times. 
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From above observations, we can see that the drug release was fastest from 
the ALG particulates, intermediate from ALG-PLL particulates and slowest from the 
ALG-PEC-PLL particulates . It also showed that release of all the three drugs from 
ALG-PEC-PLL particulates were slower and more towards sustained release in the 
alkaline medium. 
Contradictory results are reported in the literature with regard to the 
dissolution rate of ALG particulates in the acidic and alkaline media. While 
Bodmeier and coworkers (Bod meier, et al., 1989) have reported a slower release of 
drug from ALG particulates in acidic solution than in alkaline solution, 0stberg and 
coworkers ( 1994) have reported a faster release in acidic solution. Our observation 
was similar to the results reported by Bod meier et al (1989). This could be attributed 
to the differences in the chemical composition of the sodium ALG used by the 
different groups. Commercially available sodium ALG comes in various grades that 
differ in the G/M ratios and the level of free acid functions (Timmins, et al., 1992). 
Since the ALG used by Bod meier's group ( 1989) and us were similar and obtained 
from the same supplier (Sigma Chemicals, St. Louis, USA, 2% solution with a 
viscosity of 3,500 cps), it is reasonable to assume a similar chemical composition 
and hence, similar physical properties. 0stberg and coworkers (1994) used sodium 
ALG from a different source (Pro nova Biopolymer, Dram men, Norway, MW 200,000-
270,000 Da) which had a different composition from that of ours. 
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5.4.4. Release profiles and gelation time 
Some research groups have tried to increase the gelation time of ALG 
particulates. For example, Murata et al (1996) increased the gelation time of ALG 
particulates to 48 h and incubated the particulates in CaCI 2 at 37 ' C in order to 
modify the release pattern. The particulates were supposed to be more robust. 
However. their results showed that ALG particulates disintegrated gradually in the 
dissolution test solution (JP XII 2nd fluid, pH 6.8), and about 90% of the drug was 
released after 45 min (Murata, et al., 1996). This release profile was similar to our 
ALG particulates, prepared by 10 min gelation time, in phosphate buffer (pH 7.5) . 
It is evident coating ALG with PLL alone can not improve drug release profile in 
alkaline medium beyond a certain extent. For any significant improvement in the 
release profile a different approach has to be adopted. We achieved this by 
incorporating PEC in the particulates. 
The effect of gelation time on the performance of ALG-PEC-PLL were 
studied. This was done by comparing the release profiles of theophylline from ALG-
PEC-PLL particulates, prepared by 10 and 20 min gelation time, in 0.1 M HCI solution 
and phosphate buffer (Figure 18). In 0.1 M HCI solution the t90u;. of ALG-PEC-PLL 
particulates with 10 and 20 min gelation time were 4 and 6 h, respectively, while in 
phosphate buffertheirlg0.,_ were 2 and 3.5 h, respectively. The particulates prepared 
by 20 min gelation time demonstrated a slower release in both dissolution fluids. 
Since the interaction between calcium and PEC was relatively slow, the relatively 
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longer gelation time would allow the interaction to complete. The results indicated 
that gelation time played an important role in the intensity of the ALG-PEC-PLL 
particulates which affected the release pattern. Therefore, we choose 20 min as the 
optimal gelation time for the preparation of ALG-PEC-PLL particulates. 
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5.4.5. Release profiles of ALG·PLL I and II particulates 
The release profiles of ALG-PLL I (PLL coated on ALG particulates) and 
ALG-PLL II (PLL incorporated in the matrix of the ALG particulates and also as a 
coat outside the particulates) were similar. Since the reaction between polyanions 
and polycations itself was expected to be very rapid, the rate limiting step was 
probably the diffusion of PLL 1nto the ALG gel core, where the free diffusion of PLL 
was restricted by the gel porosity and the relative MW of PLL. During the preparation 
of ALG-PLL II particulates , we assumed that at the beginning of the formation of 
calcium-ALG gel, the gel porosity was large, and PLL could diffused into the calcium-
ALG gel core to interact with ALG inside. 
We used indomethacin as the model drug in this comparative study, and the 
release profiles showed the slower release of the drug from ALG-PLL II particulates 
in phosphate buffer (Figure 19). t50.,. of ALG-PLL I particulates was 1.92 hand t50 ... 
of ALG-PLL II particulates increased to 2.8 h. Besides the micrographs of the 
structure of the particulates, this result also proved our assumption that ALG-PLL II 
particulates had cross-linkings between ALG and PLL inside the particulates. 
However, PLL is known for its immunogenic activity, thereby increased usage of PLL 
is not suitable for the delivery system. Hence, ALG-PLL II particulate still was not 
the optimal particulate formulation. In this study, we also used PEC as an ingredient 
to strengthen the central structure of the particulates. ALG-PEC-PLL particulates 
had a sustained drug release pattern similar to ALG-PLL II particulates. 
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5.4.6. Effect of MW of PLL on drug release 
It has been reported that PLL of low MW produced a relatively permeable and 
robust membrane whereas a high MW produced capsules with the reverse 
characteristics (Shimi, 1991 ). Since the strong strength of the particulates was 
desirable for this drug delivery system as well as the low permeability of the 
particu lates, we selected PLL with low M'vV. 
ALG-PLL I particulates containing indomethacin were prepared using two 
different low MW of PLL, 22,000 Da and 48,000 Da. The release of indomethacin 
from the two particulates in alkaline buffer (pH 7 .5) are given in Figure 20. There 
was a slight difference in their release. Particulates prepared with the high MW PLL 
had a faster and higher release than that with the lower MW PLL. The particulates 
with PLL MW 48,000 were less robust than that with PLL MW 22,000 resulting in 
faster release. These results were similar to the former results reported by Shimi 
(1991 ). They suggested that PLL of low MW (-22,000) was optimal in forming 
robust capsules which were relatively impermeable to the high MW species. For 
most of the particulates prepared in this project, PLL with 22,000 Da was chosen . 
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5.4. 7. Effect of drying techniques on drug release 
Drying technique had a profound effect on the drug release profile . Using 
indomethacin as the model compound, ALG and ALG-PLL I particulates were 
prepared by both air-drying and freeze-drying techniques. The air-dried particulates 
gave a higher and faster release of the encapsulated drug and the freeze-dried 
particulates gave a more sustained release (Figure 21 ). The tg0. ,, of indomethacin 
for the air-dried ALG and ALG-PLL I particulates in phosphate buffer were 1.95 and 
1.3 h, respectively, and their t90,,, for freeze-dried ALG and ALG-PLL I particulates 
were 7.02 and 8.1 h. respectively. Freeze-drying technique resulted in forming 
honey-comb like structure inside the particulates . It is speculated that this would 
increase the tortuosity factor. which in turn would reduce the diffusion rate of the 
drugs. Freeze-dried particulates provided a slower and more sustained release 
which was one of the aims of this project. Therefore, for all our particulates, we used 
freeze-drying technique. 
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5.4.8. Mechanism of drug release and release kinetics 
The mechanism of release in all the particulates would be a combination of 
diffusion and erosion (Timmins, et al., 1 992). Drug release from intact particulates 
would be predominantly by diffusion. ALG particulates being more labile are 
expected to be prone to erosion. The cross-linking in calcium-ALG gel gets 
destroyed as the calcium ions are exchanged in the presence of monovalent cations. 
Although morphologically there may not be a significant change in the swelling 
characteristics of the matrices, the gel structure that retards drug release gets 
destroyed by the loss of calcium ions (eJstberg, et al., 1994 ). The ALG-PEC-PLL 
particulates with a rigid PEC gel inside would be expected to resist erosion and 
prolong drug release. We chose a PEC with a low degree of methoxylation (28%) 
that was expected to be more soluble in water and able to form a gel with calcium 
ions relatively easily (Ashford, et al., 1994 ). It should be possible to choose ALG 
and PEC with different chemical compositions to custom design the release profile 
desired for a particular drug. 
To elucidate the kinetics of drug release from the particulates the percentage 
of drug remaining to be released (Q) were plotted as a function of time (t) in the 
following equations: 
Q = k t 
In Q = k t 
Q =kt112 
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zero order equation 
first order equation 
square root time equation 
Linear regression analyses were performed for the three equations of straight 
lines and their correlation coefficients (R2 ) were determined. These values are given 
in Table 5. The release rate could be described a3 following first order or square-
root time process depending on the drug load. For theophylline particulates (drug 
load 23-26%) the release rates were closer to first order process both in acid and 
alkaline solutions. For chlorothiazide (drug load 45%) and indomethacin (drug load 
47%) particulates the amount of drug released in the acidic medium were 
proportional to the square root of time. Their release in the alkaline medium could 
be described either as first order or square root time process. This is in general 
agreement with the release mechanisms described for reservoir systems without a 
rate controlling membrane. in which there is an initial burst followed by a slower 
release that is proportional to the square root of the time (Baker. 1987). 
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Table 5. Correlation coefficients (R2) calculated using different kinetic orders of drug release from particulates 
In 0.1 M HCI 
Zero-order First-order t'l2 
R:r ALG ALG- ALG-PEC- ALG ALG- ALG-PEC- ALG ALG-PLL AlG-PEC-
PLL PLL PLL PLL PLL 
Theophylline 0.55 0.77 0.84 0.92 0 .91 0.96 0.79 0.95 0.98 
Chlorothiazide 0.11 0.82 0 .81 0.84 0.88 0.83 0.91 0.97 0.96 
Indomethacin 0.84 0.91 0.89 0.86 0.91 0.89 0.97 0.91 0.99 
In phosphate buffer pH 7.5 
Zero-order First-order t'/2 
~ ALG AlG- ALG-PEC- ALG ALG- ALG-PEC- ALG ALG-PLL ALG-PEC-
PLL PLl PLL Pll PLL 
Theophytline 0 .34 0 .38 0 .69 0.91 0.86 0.91 0.58 0.62 0.88 
Chlorothiazide 0 .68 0 .67 0.84 0.92 0.99 0.99 0 .88 0.88 0.97 
Indomethacin 0.79 0.89 0.93 0.97 0.99 1.00 0 .94 0.97 0 .96 
5.5. In vitro bioadhesive strength studies 
5.5.1. Tensile strength test 
The tensile strengths of polymer films were measured using rat's intestinal 
mucosa as the binding surface . The modified tensiometer served the purpose quite 
well and helped in distinguishing between the polymer films studied . Between 
chitosan and sodium alginate. the former had more than tw1ce as large tens11e 
strength (Table 6). This could be attributed to the electrostatic force of attraction 
between the positively charged chitosan and the negatively charged mucosa . The 
bioadhesion of the negatively charged sodium alginate was attributed to the less 
strong hydrogen bonds. Both alginate 1.5% and 2% were tested and their tensile 
strengths were not statistically different (p > 0.05). Although the tensile strength did 
give us an idea of the type of binding that could be anticipated, it was less relevant 
to our project since the final use of the polymer was in the form of particulates and 
not films . 
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Table 6. Tensile strength measurement of polymer films when applied to rat's 
intestinal mucosa 
Materials 
Sodium ALG (2%) 
Sodium ALG (1.5%) 
Chitosan ( 1%) 
n 
8 
8 
8 
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Mean force 
(N/cm-2 ) 
380 .15 
327.92 
746.48 
so 
56.32 
63.14 
102.79 
5.5.2. Falling liquid-film test 
To test the bioadhesive property of microspheres. Rao and Buri's ( 1989) 
method has been widely accepted (Pimienta, et al., 1990; Kamath, et al., 1995). We 
adapted this method to test our particulates and the percentage of particulates 
adhering to stomach/intestine was considered as a primary index of the bioadhesive 
property of the particulates (Table 7). The results indicated that this method was 
more qualitative rather than quantitative in nature. Silicon coated glass beads (0. 7-
1 .1 mm in diameter}. used as the control, had no bioadhesive property at all . These 
beads had comparable surface area to the test polymeric particulates and hence, 
were considered adequate as a control. In contrast. the test particulates, ALG. ALG-
PLL and ALG-PEC-PLL. were 100% adhered to both the stomach and intestinal 
mucosae. Thus. from these results it is reasonable to conclude that ALG. ALG-PLL 
and ALG-PEC-PLL particulates could be expected to have good bioadhesive 
property. 
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Table 7. Percentage of bioadhesive particulates adhering to stomach and 
intestine segment after washing with 0 .1 N HCI and phosphate buffer 
% particulates adhering (n = 5) 
Materials Stomach Intestine 
Siliconized glass beads (control) 0 0 
ALG particulates 100 100 
ALG-PLL particulates 100 100 
ALG-PEC-PLL particulates 100 100 
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5.6. Transport study 
Use of Caco-2 cell monolayers for an in vitro estimation of the extent of drug 
absorption by oral route is well documented (Artursson 1990, Schipper et al 1996, 
Brayden 1997). Mannitol is typically used as the paracellular tight junctional marker 
(Brayden 1997). One of the limitations of the study is that only solutions can be test 
samples and drug loaded microspheres can not be used as test samples. 
In this experiment, mannitol was used as the model drug for transport study. 
As shown in Table 8. Papp of mannitol ranged from 0.65 X 10.7 to 1.1 X 10·7 em/sec 
in the control situation. and the P appgradually increased and reached a plateau value 
of 1.1 x 1 o·7 em/sec in 90 minutes. This result obtained was consistent with those 
reported by other research groups (Jorgensen, 1993 and Schipper. et al., 1996). 
The P app value indicated that the Caco-2 monolayer on the filter was totally confluent 
and integrate. 
The P app of mannitol was affected in the presence of the test polymer 
solutions. Both test solutions contained 1% ALG and differed in their PEC content. 
viz .. one had 1% and the other had 2% (w/v) PEC. Addition of PEC beyond 2% 
resulted in a very viscous solution that was difficult to handle. The time courses for 
the effects of test samples on the permeability of mannitol in Caco-2 monolayer were 
obtained by plotting mean P app as a function of time. From Figure 22 . we can see 
for both the test samples there were significant enhancements in the apparent 
permeability of mannitol. In 30 minutes, the test sample with 1% PEC reached 87% 
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peak Paoo value (3.0 x 1 o-7 em/sec) whereas, the test sample with 2% PEG reached 
its peak p app (3 .1 X 1 0"7 em/sec). There was no statistical difference (p>0.05) in their 
plateau Paoo (range 2.9-3.0 x 10·7 em/sec) which was attained in about 60 minutes. 
The three-fold increase compared to the control, in P aoo of mannitol across Caco-2 
monolayers in the presence of ALG and PEC could be of significant importance in 
improving oral drug delivery of poorly absorbed drugs. Since mannitol is well 
recognized as a paracellular tight junctional marker (Brayden 1997), it may be 
speculated that alginate and pectin alter the cellular tight junctions, resulting in a net 
increase in mannitol transport across the Caco-2 cell monolayers. 
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Table 8. Effect of ALG and PEC on the mean permeability of mannitol across Caco-2 cell monolayers 
Time Mean P.,1,., value of mannitol X 10·' (em/sec)± SO (n = 3) (min) 
Control 1% ALG an<l1% PEC 1% ALG and 2% PEC 
30 0.621 ± 0.037 2.554 ± 0.22 3.102 ± 0.328 
I 
_... 60 0.896 ± 0.075 2.841 ± 0.079 2 .517 ± 0.341 
_... 
~ 
I 90 1.103±0.027 3.03 ± 0.062 2 .861 ± 0.372 
120 1.087 ± 0.09 3.02 ± 0.081 2.825 ± 0.225 
150 1.143 ± 0.034 2.91 ± 0.098 2.87 ± 0.226 
180 1.116 ± 0.157 2.884 ± 0 046 2.849 ± 0.229 
0 31 (f) +I 
u Q.) 
(/) I 
--E l 
I ------ Control ~ 2 
r-
-o- 1% ALG & 1% PEC I 
0 
..--
-----..- 1% ALG & 2% PEC 
>< 
B 
·c: 
C\1 
E 
0.. 
0.. 
C\1 
a.. 
0 
0 30 60 90 120 150 180 
Time (h) 
Figure 22. Transport of mannitol from ALG and PEC solutions across 
Caco-2 cell monolayers (n = 3) 
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It is generally believed that achieving an absorption enhancing effect quickly, 
with the simultaneous presence of high drug concentration at the site, is difficult to 
achieve (De Boer, 1994 ). In our case, the actual dosage form, viz .. drug-loaded 
ALG-PEC-PLL particulates, would also have bioadhesive property. This would 
mean that these particulates could be expected to adhere to the mucosal sites in the 
gut and exhibit the permeability enhancing effect of ALG and PEC within 30 minutes 
of contact with Caco-2 monolayers. It would be reasonable to expect that our drug-
loaded particulates would have the combined advantages of enhanced permeability 
and increased drug concentration at an absorption site. 
It is reported that PLL exercises a permeability enhancing property on 
endothelial and epithelial tissues (McEwan, et al., 1993 ). The changes in 
permeability were more dependent on the amount of positive charge in the 
polycations than the type of cationic polypeptide used, and were related to 
alterations in membrane properties (Tzan, et al., 1993) as well as tight junctional 
integrity (McEwan, et al., 1993; Bentzel, et al., 1987). In the formulation of ALG-
PEC-PLL particulates, PLL was presented in very small concentration and was 
neutralized with negatively charged ALG. Hence, we do not anticipate PLL by itself 
to exercise any of its permeability enhancing property. 
The in vitro results from release, bioadhesive strength and transport studies 
showed that this novel particulate system, ALG-PEC-PLL had a good potential to be 
used as a carrier for poorly absorbed and/or erratically absorbed drugs by mucosal 
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route. Further work to test the drug loaded particulates in an in vivo animal model 
will be done in future in the laboratory. 
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6. CONCLUSIONS 
In summary, the in vitro studies performed demonstrated that the three 
particulates, ALG, ALG-PLL. ALG-PEC-PLL, had good bioadhesive properties to 
both stomach and intestinal mucosal sections of rat's gut. ALG and PEC were used 
as core materials. PEC strengthened the particulates by modifying the core 
structure of the particulates, and PLL strengthened the particulates by forming 
permanent outer layer with ALG. The drug release was fastest from the ALG 
particulates. intermediate from ALG-PLL particulates and slowest from the ALG-
PEC-PLL particulates in both acidic and alkaline dissolution medium. Among the 
three particulates, ALG-PEC-PLL was the most suitable particulate in sustaining 
drug release, and its stability in acidic medium made it a potential carrier for acid-
labile drugs. Use of ALG and PEC resulted in increased absorption of mannitol 
across Caco-2 monolayer by about three times. Therefore, use of ALG-PEC-PLL 
particulates is expected to combine the advantages of sustained release, 
bioadhesion and absorption enhancement. This particulate system may have 
potential use as a carrier for poorly absorbed drugs by oral administration . 
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Chapter II 
1. INTRODUCTION 
Hydrophilic drugs including peptides and proteins in simple solution 
formulations usually have very low bioavailability when administered by mucosal 
route. such as nasal and oral route. The low mucosal absorption can be the result 
of poor membrane permeability, enzymatic degradation or due to the 
physicochemical properties of the drug. To overcome this problem. many research 
groups have investigated to use absorption enhancers to facilitate the transport of 
drugs and improve their bioavailability (Wheatley. et al.. 1988: Aungst. et al.. 1 988a 
and O'Hagan. et al., 1990). Additionally, the rapid removal of the drug from the 
absorption sites by mucus turnover also results in the low bioavailability for this class 
of drugs. It is conceivable that the drug must have sufficient time to achieve 
maximal contact with the membrane before efficient transport can occur. It has been 
known that BODS can be retained in contact with the mucosa for a prolonged period 
and the process of absorption can be improved because of the interaction of 
bioadhesive systems with the mucus. The development of bioadhesive particulates 
is discussed in Chapter I. In this chapter, we will describe another approach, using 
absorption enhancers to increase the low permeability of the epithelial membrane. 
Eventually the two approaches would be combined so that a suitable enhancer could 
be carried by the particulate carriers. These particulate carriers would be novel and 
-119· 
would be expected to have particulates' protective and bioadhesive properties and 
enhancer's permeation enhancing property. These unique particulates would then 
be very suitable to deliver the delicate peptide and protein drugs through mucosal 
routes that would be more patient compliant. 
1.1 Absorption enhancers 
Absorption enhancers are compounds that can increase the mucosal 
membrane permeability and hence the absorption of poorly permeable drugs that 
are coadministered with the enhancer. In general, enhancers improve the 
absorption of the drug by one or several of the following mechanisms: i) increase the 
membrane fluidity and reduce the viscosity of the mucus layer, thereby increase 
membrane permeability (Yamamoto, et al., 1990 and Hussain, et al., 1990); ii) inhibit 
proteolytic enzymes at the absorption site (Yamamoto, et al.. 1990 and Gros, et al., 
1990); iii) transiently loosen the tight junctions between certain epithelial cells 
(lasdun, et al., 1989); iv) increase paracellular or transcellular transport (Lasdun, et 
al., 1990); v) dissociate protein aggregation (hanson, et al., 1989); vi) initiate 
membrane pore formation (lejczak, et al., 1989). These mechanisms were 
summarized in Table 9. Various types of absorption enhancers have been 
evaluated. Examples include surfactants, steroidal detergents (bile salts), salicylate 
and analogues, EDTA and other chelators and Enamines/N-acyl amino acids 
(Aungst, 1994 ). The results have shown that they do affect membrane permeability, 
and the proposed mechanisms are enumerated in Table 10. However, most 
absorption enhancers are fraught with the problem of toxicity such as, cell erosion, 
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excessive mucus discharge, membrane protein removal, etc. (Gizurarson et al., 
1990; Hermens et al., 1990; Jorgensen. et al.. 1993). The practical use of these 
absorption enhancers required toxicological assessment and in particular. their 
potential to cause irritation and their effect on the integrity of the epithelium. For 
instance, steroidal surfactants have been by far the most frequently evaluated for 
facilitating the nasal absorption of peptide and protein drugs, and some steroidal 
surfactants even have been examined in clinical trials . However, in most cases. 
there were adverse reactions such as stinging or burning sensation, discomfort. or 
a certain degree of pain, indicative of irritation potential. Thus, although many 
compounds have been studied to determine an acceptable balance between 
absorption enhancing and toxicological effects, only a few have been found 
acceptable (Ennis et al.. 1990; Chandler, et al., 1991 ). As result the quest for a 
good absorption enhancer is still continuing. Researchers in the field of bioadhesion 
and absorption enhancers are now focusing on natural compounds (Lehr 1994 ). in 
search of novel bioadhesives and enhancers. Although melittin is generally 
considered as toxic substance, its action as a membrane fusion substance has a 
strong concentration dependency (Ohki et al. 1994 ). Ours is a curiosity-driven 
research and we envisage that the concentration of melittin could be optimized, and 
used as an effective absorption enhancer, without any undesirable effects on 
membranes. 
Table 9. Possible mechanisms of enhancing transmucosal absorption . 
A. Barrier disruption (permeability enhancement) 
1. Mucus layer 
2. Transcellular 
3. Paracellular (tight junctions) 
4. Epithelial cell loss 
B. Altered physicochemical properties of drug in vehicle 
C. Inhibition of metabolism 
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Table 10. Proposed mechanisms of mucosal membrane permeability 
enhancement for various enhancers (Aungst. 1994) 
Surfactants 
Extraction of membrane proteins or lipids 
Membrane fluidization 
Steroidal detergents 
Extraction of membrane proteins or lipids 
Membrane fluidization 
Reverse micellization in membrane, creating aqueous channels 
EDTA and other chelators 
Chelates calcium at tight junctions, increasing paracellular transport 
Salicylate and analogues 
Decreases nonprotein sulfhydryls in membrane 
Interacts with membrane proteins 
Calcium chelation 
Enamines/N-acyl amino acids 
Surface-active: membrane fluidization or extraction of membrane 
proteins or lipids 
Calcium chelation 
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1.2. Melittin 
In this study to improve the membrane permeability of poorly absorbed 
drugs, we have investigated the possibility of using melittin as a novel absorption 
enhancer. Melittin. the major active ingredient of honey bee venom. Apis me/litera, 
consists of 26 amino acids (sequence see Figure 23). Similar to other membrane-
binding peptides and membrane proteins, melittin is predominantly hydrophobic. 
The peptide has a net charge of +6; four of these charges are in the highly basic C-
terminal tetrapeptide sequence Lys-Arg-Lys-Arg. There are no acidic groups in 
melittin . Although it has high proportion of hydrophobic sidechains, melittin is very 
soluble in water(> 250 mg/ml). Melittin reaches membranes through the aqueous 
phase. In aqueous solution melittin adopts different conformations and aggregation 
states which result from two opposing forces: the hydrophobic effect promotes self-
association, and the high positive-charge density of melittin resists self-association . 
Its conformation depends on several factors including peptide concentration, pH, 
ionic strength and the nature of the negative countreion (lauterwein, et al., 1 980; 
Quay, 1 983; Dawson, et al., 1978 and Knoppel, et al., 1979). 
Melittin has been used as a model compound for studying the general 
features of membrane proteins and their interactions with membrane lipids (DeGrade 
et al, 1982; Tosteson et al 1987; Stankowski et al., 1991 and Benachir et al. , 1995). 
There is no consensus on the mechanism of interaction of melittin with membrane 
lipids because several actions ofmelittin on membranes have been suggested, such 
as hemolytic activity, voltage-gated channel formation and melittin-induced bilayer 
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micellization and fusion, which are not necessarily related (Dempsey, 1990). It is 
used in homeopathy for treating allergies, inflammation and burns (Picard et al., 
1995). Its action as a membrane fusion peptide has been reported to be very 
efficient and have a strong concentration dependency (Thomas, et al. , 1994 ). Based 
on these results, we envisage that the concentration of melittin could be optimized, 
and it could be used as an effective absorption enhancer without any undesirable 
effects on membranes. 
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Gly-lle-Giy-Aia-Vai-Leu-Lys-Val-Leu-Thr-Thr-Giy-Leu-Pro-Aia-Leu-lle-Ser-Trp-lle-
Lys-Arg-Lys-Arg-Gin-Gin-NH 
Figure 23. Amino acid sequence of melittin 
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It is known that both metabolism and low membrane permeation can 
contribute to the poor bioavailability of many drugs including peptides and proteins 
administered by mucosal routes. To address the problem of metabolism, many 
delivery systems and enzymatic inhibitors have been investigated. Particulate 
delivery system is one of these applications which has been extensively studied for 
the delivery of peptides and proteins (Wood. 1 982; 'vVang, et ai., 1991; Sah , et al.. 
1994; Yeh. et al., 1995 and 1996). One of the advantages of the particulate system 
is that it could protect the peptides and proteins from metabolism occurring at the 
surface of the epithelial membrane to some extent. By incorporating melittin, which 
is itself a peptide. along with the drug in a particulate delivery system, we anticipate 
that a sufficient quantity of the drug and the enhancer will be delivered at the 
absorption site . 
1.3. Caco-2 cell line for the study of absorption enhancers 
The efficacy of absorption enhancers on the permeability of epithelial 
membrane has been investigated in numerous in vivo and in vitro models. Various 
epithelial cell lines have been reported to be used as in vitro model membranes for 
the study of drug transport and metabolism at biological barriers. The in vitro cell 
culture model has many advantages over conventional methods for the study of 
absorption enhancers, which include rapid assessment of the permeability of a drug, 
elucidation of mechanisms of the various pathways in transepithelial transport, easy 
construction of dose-response curves with high degree of reproducibility. 
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Among these, the Caco-2 cell line , originating from a human colonic 
adenocarcinoma, is the most commonly used cell line for absorption enhancer 
studies because it resembles the human intestinal epithelial membrane in that it 
differentiates to express structures similar to that of small intestinal villi. It has been 
widely used to study drug transport mechanisms (Artursson. 1990a, 199Gb; Thwaites 
et al., 1996; Rubas et al., 1996; Yamashita et ai. , 1997), cytotoxicity (J0rgensen. et 
al. , 1993 and Schipper, et al., 1996;), and absorption enhancement (Andernberg et 
al. 1992, 1993; Schipper et al., 1996 and Werner et al., 1996), which have been 
described in section 1.5.2.4. , Chapter I. 
In this study, we investigated the in vitro cytotoxicity of melittin on the Caco-2 
cell membrane using MTT assay to establish its safe concentration range. We also 
demonstrated the effective and safe use of melittin as an absorption enhancer to 
transport mannitol across Caco-2 cell monolayers. 
-128-
2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Chemicals and equipments 
Melittin (79% purity), mannitol, Dulbecco's Modified Eagle's Medium (DMEM, 
with 4.5g/L glucose), Non-essential amino acids (NEAA), and Trypsin (0.25%)-EDTA 
(1 mM) were all purchased from Sigma Chemicals, MO, USA. Fetal calf serum 
(FCS). penicillin-streptomycin (5,000 I. U./ml and 5,000 pg/ml) and sodium 
bicarbonate solution (7 .5%, w/v) were obtained from Gibco BRL. Life Technologies. 
NY, USA. Potassium phosphate monobasic, dibasic were purchased form Fisher 
Scientific Co. , NJ, USA. Scintillation cocktail (Formula 989®) was purchased from 
Packard Instrument Company Inc. Meriden. CT. USA. MTI (3-[4.5-dimethylthiazol-
2-yl]-2.5-diphenyl-tetrazolium bromide) was purchased from Bio-Rad Laboratories, 
Inc. CA. USA. 
Water-jacketed incubator (lsotemp® Incubator Model 546, Fisher Scientific 
Co., NJ, USA) was employed to provide a suitable environment for cells growth. 
Hund Wetzlar Wilovert® microscope (Wetzlar/Nauborn. Germany) and 
Hemacytometer (Hausser Scientific, PA, USA) were used for cells counting . Tissue 
culture flasks and pipettes were purchased from Fisher Scientific Co., NJ, USA. 
Ninety six-well tissue culture plates (Costar. MA, USA) were used for MTI assay. 
Transwell® 6-well plate inserts (pore size 0.4 pm. Costar, MA, USA) were used for 
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the transport study. 
2.1.2. Instruments 
A Microplate-Reade~ (Model 550, Bio-Rad Laboratories, Inc. CA. USA) was 
used to determine the absorbance in MTT assay, and a liquid scintillation counter 
(Beckman LS 5000 TO, CA. USA) was used to measure the radioactivity of :.:c 
samples. 
2.1.3. Radioisotope 
14C-mannitol (specific activity: 50 mCilmmol, 0 .25mCi/mL) in ethanol solution 
was purchased from Sigma Chemicals, MO. USA. 
2.1.4. Cell line 
The Caco-2 cell line was obtained from American Type Culture Collection 
(MD, USA) at passage 17 and used for MTT assay and transport study. 
2.2. Methods 
2.2.1. Preparation of Caco-2 monolayers 
For MTT assays, the cells (passages 26-29) were harvested with trypsin-
EDT A and seeded in 96-well tissue culture plates at a density of 104 cells/well, and 
cultivated with completed DMEM. About 100 J.ll DMEM was added into each well 
and was changed every 48 hr. The cells were incubated at 37 a c. in an atmosphere 
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of 5% C02 and 95% air for 21 days before starting MIT assays . 
For the transport studies, preparation of Caco-2 cell monolayers was the 
same as that discussed in section 4.2.6 .2. Chapter I. Briefly , Caco-2 cells (passages 
26-29) were cultivated on polycarbonate filters of Transwell® inserts at a seeding 
density of 3 x1 05 cells/well. After 21-23 days of seeding, the cells were su itable for 
conductmg the transport study. 
2.2.2. MTT assay 
The effect of melittin on intracellular dehydrogenase activity, which has been 
used to indicate the viability of the cells, was determined by the MTT method . MTT 
is a tetrazolium salt that can be cleaved by mitochondrial dehydrogenases in living 
cells to give a dark-blue formazan product (Lappalainen, et al., 1994 ). Damaged or 
dead cells show reduced or no dehydrogenase activity. Thus the amount of 
formazan produced during the MTT assay could be used as an index of melittin's 
effect as a cellular toxin. For the MIT assay, the cells were first incubated with 
various concentrations of melittin ranging from 0.61 !JM to 5.45 !JM in 100 !JL DMEM 
for a period of 2 hours at 37 'C. Then they were washed with 100 !JL phosphate 
buffer saline (PBS), and incubated for another 4 hours at 37 ' C with 100 !JL of MTT 
in PBS. Thereafter, the solution was removed and formazan crystals in the cells 
were dissolved by adding 200 !JL dimetheyl sulfoxide (DMSO). The resulting color 
was measured at 570 nm using a microplate reader. The control consisted of 100 
1-1L DMEM without melittin . 
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2.2.3. Transport study of 14C- mannitol 
The procedure was similar to that used for the transport study of the polymer 
solutions discussed in Section 4.2.6.4-6 . Chapter I. Briefly, in all the transport 
experiments , DMEM was used as the solvent and medium. It was added to the 
receiver compartment of the Transwell® containing the cultured Caco-2 cell 
monolayers. Mannitol (0.1% w/v) was dissolved in DMEM and was spiked with ' 1C-
mannitol (0 .25 uCi/ml) for liquid scintillation assays . To this solution different 
amounts of melittin were added to obtain four test solutions. 0.34 1-JM , 0 .68 1-1M . 1.2 
1-1M and 1.5 1-JM . The control solution consisted of only mannitol in DMEM . The test 
solution was added to donor compartment, and the transport studies were conducted 
for a duration of 3 hours . Aliquot samples (100 u l) were taken from the receiver 
side every 30 minutes, which was replenished with fresh DMEM. The donor side 
solutions were also analyzed to determine the total radioactivity of the test solution 
applied to the cells . To 100 ul of the aliquot samples, 5 ml scintillation cocktail 
were added before quantifying in the liquid scintillation counter. The background 
radioactivity was determined using DMEM. The P app was calculated using the 
equation described in Section 4.2 .6.6. Chapter I, and the mean P app ± SO were 
determined. 
2.2.4. Statistical Evaluations 
In this study, Sigma plot® 4.0 and SPSS 7.5 for Windows program were used 
to analyze the data. Statistical differences were investigated using one-way AN OVA 
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followed by Bonferroni t-tests for multiple comparisons. Differences between group 
means were judged significant at p < 0.05. Results are expressed as mean ± SO 
(n= 6 for MTT assay and 3 for mannitol transport study). 
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3. RESULTS AND DISCUSSION 
3.1. MTT assay 
Melittin produced a concentration dependent decrease in the dehydrogenase 
activity on Caco-2 cell monolayers (Figure 24 ). For making comparative analysis, 
the dehydrogenase activity of the control sample was considered 100%. Compared 
to control there was no significant (p>0.05) decrease in the enzyme activity for 
melittin concentrations below 2.42 ~M. Melittin concentrations above 2.42 ~M 
caused a significant (P < 0.05) decrease in cellular dehydrogenase activity and the 
4.5 ~M solution produced 50% inhibition (IC50 ) of the dehydrogenase activity. From 
these results . we could infer that a melittin concentration below 2.42 ~M would 
produce negligible cytotoxicity and could be considered safe. However, to ensure 
further safety we limited the highest melittin concentration to 1.5 ~M for the drug 
enhancement study. 
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3.2. Transport study of 14C- mannitol across Caco-2 monolayers 
Mannitol is typically used as a paracellular tight junctional marker (Brayden, 
1997). The cumulative percentage of mannitol transported across the Caco-2 cell 
monolayers are indicated in Figure 25. The concentrations of melittin chosen for 
transport study were well within the safety limit (2.42 ~M) deduced from the MTT 
assay. 'vVith 1.20 ~M and 1.50 1-JM of melittin, the percentage of mannitol transported 
across Caco-2 cell monolayers in three hours increased by 3.5 fold compared to the 
control. 'Nith the lower concentrations of melittin viz. , 0.34 and 0.68 ~M . there were 
no significant (P>0.05) differences from the control. The Pao;J values of mannitol 
were calculated at different time intervals (Figure 26). The P aoo for mannitol from the 
control sample ranged between 0.8-1.0 x 1 o·7 em/sec which is in agreement with the 
published report of Schipper et al. ( 1996). This is also an evidence for the 
confluence and cellular integrity of the Caco-2 cell monolayers. The Pdpo values 
obtained with the control solution, and with 0.34 ~M and 0.68 ~M of melittin solutions 
were not statistically (P>0.05) different. However, the Paop for 1.20 and 1.50 ~M of 
melittin solutions were similar and statistically different (P<0.05) from the control, 
0.34 ~M and 0.68 1-1M solutions . From the transport study it is apparent that it is 
necessary to reach a critical threshold concentration of melittin in order to evoke its 
absorption enhancing effect. Permeabilization of membranes at low concentrations 
of melittin has been attributed to alteration of the organization properties of 
membrane lipids (Dempsey, 1990). Other investigators have shown that melittin 
induces a lamellar (bilayer) to micellar phase transition in model phospholipid 
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membranes when the melittin concentration in the bilayers is between 3 and 5 mol% 
(Dempsey, et al.. 1987 a and 1987b ). We speculate that a similar mechanism is 
responsible for the increased permeability of Caco-2 cells. It is clear from our 
toxicity determinations that these transitions are not extensive enough to cause cell 
lysis in this cell line. 
Since this critical concentration of melittin ( 1.20-1.50 1JM) for observing an 
absorption enhancement effect is within the safe concentration limit (2.42 ~M), it will 
be worthwhile to pursue further the use of melittin as a viable absorption enhancer. 
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4. CONCLUSION 
This study indicated the possibility of using melittin as an absorption 
enhancer. At a concentration below 2.42 ~Mit did not show any cytotoxic effects on 
Caco-2 cells. 1.20-1 .50 ~M of melittin solution was able to increase the transport of 
mannitol across Caco-2 monolayer by a factor of 3.5. Further studies to determine 
the long-term safety of melittin are required to be done to prove 1ts utility as a safe 
absorption enhancer. 
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